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ABSTRACT 
An initial investigation reporting the excellent suitability of an 
MSV-induced osteosarcoma in rats as a model of the human disease has been 
confirmed and extended. Intratibial inoculation of the virus in newborn 
animals has reproducibly caused a localized, osteoid-producing tumor mass 
which is rapidly progressive and fatal (median survival = 20.0 days). The 
histologic nature, incidence, and distribution of metastatic disease in 
this tumor model are comparable in most respects to osteosarcoma in man. 
Particularly significant was the 89% incidence of metastatic pulmonary di¬ 
sease in tumor-bearing groups from 10 to 65 days of age. 
Tumor-specific cellular and humoral responses were demonstrated in 
animal groups tested between 14 and 48 days of age. Use of an in vitro 
cytotoxicity assay demonstrated a biphasic pattern to both cellular and hu¬ 
moral cytotoxicity, and the theoretical correlates and implications of 
these kinetics have been discussed. Humoral factors consistently increased 
the levels of cell-mediated immunity in untreated tumor-bearing animals. 
The efficacy of adriamycin chemotherapy in human osteosarcoma stim¬ 
ulated its use in the rat model, where its effects were twofold. The net 
effect of adriamycin treatment at two doses and a single schedule was bene¬ 
ficial due to its tumoricidal actions. Treated animals exhibited signifi¬ 
cantly retarded tumor growth and survived significantly longer than un¬ 
treated tumor-bearing controls. Importantly, adriamycin treatment was not 
associated with suppression of tumor-specific cell-mediated immunity. In 
addition, however, use of adriamycin was associated with a possibly dose- 
related in vivo and in vitro enhancement phenomenon, as treated animals dev¬ 
eloped significantly more long bone metastases than controls, and exhi¬ 
bited blocking activity in their sera. It has been postulated that this 
enhancement was caused by adriamycin-induced antigenic shedding by the tu¬ 
mor, with the consequent formation of serum blocking factors. 
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I. Introduction 
A. The Relationship between Immunity and Malignancy 
The Concept of Immune Surveillance: 
In a lecture on cancer given in 1908, the brilliant German founder 
of immunology, Paul Ehrlich, first proposed that there exists a funda¬ 
mental relationship between immunity and malignancy. In this lecture 
he stated: 
"The understanding of natural immunity represents the 
key to carcinoma... I am certain that, in the enor¬ 
mously complicated course of fetal and post-fetal 
development, aberrant cells become unusually common. 
Fortunately, in the majority of people, they remain 
completely latent thanks to the organism's positive 
mechanisms. If such mechanisms did not exist, one 
might expect carcinomas to have an enormous frequency. 
These cells may live in a latent state for 20, 30 or 
40 years before changing to a significant tumor. 
This means, in light of my theory, that there has 
been a diminution of some vital cell activity 
[which] allows the rapid, parasitic growth of cer¬ 
tain cells. "90 
Ehrlich's amazing insight was apparently not fully appreciated, 
however, as only one report (in 1924) until the last two decades 
mentioned the potential significance of host immunity as a defense 
against neoplasia. Renewed interest in immunological studies of cancer 
112 followed the landmark experiments by Foley (1953) , Prehn and Main 
(1957)^, and Klein (1966)^. These studies established the presence 
of tumor-associated antigens, and together with observations of cancer 
epidemiology, laid the foundations for a most powerful influence on 
cancer research -- the theory of inmunologi cal surveillance. 
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A1 though clearly suggested by Ehrlich in 1908, the theory in its 
modern form was formulated by Lewis Thomas in a discussion of trans- 
316 plantation inmunity in 1959. On considering the "underlying meaning 
of homograft rejection, as a biological phenomenon", Thomas proposed 
that "homograft rejection will turn out to represent a primary mecha¬ 
nism for natural defense against neoplasia". Stimulated by this concept, 
42 Burnet in 1963 first used the term "surveillance" to characterize 
this relationship. 
Stated more precisely, the thesis of immune surveillance theory is 
that when aberrant cells with prol iferative potential arise in the body, 
they carry new antigenic determinants on their cell surface. When a 
sufficient amount of new antigen is present, a cellular, mainly thymus- 
dependent immunological response is initiated which eventually elimi¬ 
nates the aberrant cells in essentially the same way that a homograft 
43 is destroyed. 
While of great clinical and heuristic importance, this theory has 
at its foundation a sound evolutionary explanation. Though some have 
casually proposed that the raison d'etre of the irnnune system lies in 
131 132 its elimination of neoplastic cells. Good and Finstad ’ have 
studied in depth the evolution of the immune response, and draw some 
very intriguing conclusions. In brief, they have proposed that the 
vertebrate capacities for malignancy and immune competence developed 
concomitantly in phylogeny. Both, they suggest, evolved as a function 
of a more basic impulse to cellular variation in higher, vertebrate 
forms. While the capacity for somatic mutation per se could have been 
of major survival advantage, "malignant adaptation" may have either 
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been an undesirable side effect, or teleologically, have had its own 
survival value in protecting ecological niches from exhaustion by groups 
of each vertebrate form. The immunological adaptation, in turn, pro¬ 
gressively developed a capacity for surveillance against the threat of 
malignant adaptation. From this view, as stated by Burnet in his 1960 
Nobel prize speech, "the faculty of immunological recognition becomes 
an intrinsic part of the homeostatic controls that maintain the body 
41 
as a going concern". 
Cited as evidence for this evolutionary theory is the inability of 
investigators to identify malignancies in invertebrate forms; the 
failure of vertebrate carcinogens to induce malignancies in, or high 
doses of irradiation to kill, these lower forms, and the congruous 
inability of investigators to define invertebrate immune cells or reac¬ 
tions. On the other hand, both cellular immunity and definite malig¬ 
nancies have consistently been described in all vertebrate forms, 
including fishes, amphibians, reptiles, birds and mammals. 
Clinical Evidence for Immunologic Surveillance: 
43 Burnet suggested that there are at least four predictions made 
by the theory of immunologic surveillance at the clinical level: 
1. There should be an increased incidence of malignancy initiated 
at ages of relative immunologic incompetence. 
2. Pathologic conditions associated with deficiencies of thymus- 
dependent immunity should be associated with a higher incidence 
of neoplasia. 
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3. Spontaneous remissions of clinically evident malignancy should 
occur. 
4. Unselected autopsies or pathologic specimens should show larger 
numbers of malignant foci than could ever develop to definite 
tumors. 
A few recent reports have elegantly reviewed the wealth of clini¬ 
cal evidence supporting these predictions; however, several points are 
noteworthy for this discussion. 
First, cancer is largely a disease of the very old and the very 
young. The age incidence of many childhood tumors is compatible with 
257 
a process initiated about the time of birth , a time of relative 
immunoincompetence. At the other extreme, consistent with thymic invo- 
12 314 lution and a decrease in immunologic vigor with advanced age ’ , 
malignant cells flourish. While humoral and re-call immunity (to pre- 
12 41 43 131 
viously experienced antigen) are adequate in the elderly * * * ’ 
1 qo QC"7 0“7 c Q1/1 
i oz,/,z/o ,o ^ responses to new and thymic-dependent antigens are 
markedly depressed. More than 95% of individuals under age 65 can be 
sensitized to dinitrochlorobenzene, whereas only 20-30% of patients 
91 
over 65 can be so sensitized. In addition, old people with malig- 
1 89 1 88 
nancies do less well with these identical or similar immunologic 
procedures than do other noncancerous patients with chronic disease, 
or normal individuals of the same age. 
Convincing evidence for the second prediction -- that pathologic 
conditions associated with diminished thymus-dependent immunity have an 
increased incidence of malignancy -- comes from two sources. The first 
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1 31 
area includes what Good calls "experiments of nature" , in which 
immunological deficiency diseases are associated with a significantly 
higher incidence of malignancy. Particularly striking are the Wiskott- 
Aldrich and ataxia-telangiectasia syndromes, conditions of defective 
ontogenetic thymus-dependent lymphoid development. In these conditions, 
malignancy has been the cause of death in fully 13 and 10% of reported 
21 2 
cases, respectively. When all acquired and congenital immunodefi¬ 
ciency disorders are considered together, a very conservative estimate 
of the incidence of malignancy is about 5%, or about 200 times the 
expected rate.^ 
The second area involves malignancy associated with long-term 
iatrogenic immunosuppression in organ (mainly renal) transplant recipi¬ 
ents. Immunosuppression for transplantation generally consists of 
azathi oprine, prednisone, anti lymphocyte serum and/or a variety of 
other methods generally intended to diminish thymus-dependent immunity. 
The incidence of de novo malignancies here is approximately 5.6% in 
patients averaging 38 years of age, or approximately 100 times the ex- 
250 250 pected rate. A remarkable fact reported by Penn is that a wide 
variety of histological malignancies have been encountered. The most 
common lesions were cancers of the skin and lips (39%), followed by 
solid lymphomas (27%), carcinomas of the cervix and uterus (8%), lung 
(5%), and miscellaneous (21%). Perhaps even more notable is the report 
334 by Woodruff that withdrawal of immunosuppressive regimens has caused 
regressions of tumors arising in transplant recipients. Some would hold 
that these data do not necessarily support immunological surveillance, 
but rather represent diminished host defenses against oncogenic viruses 
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203 qua infectious agents. Nevertheless, the variety of malignancies 
observed (including, for example, lung cancer), and the occurrence of 
"spontaneous" tumor regressions upon withdrawal of immunosuppressives 
both support a role for host tumor-specific defense mechanisms. 
"Spontaneous" tumor regressions have been well documented in other, 
non-transplant patients as well. Of 130 instances considered unequivo- 
98 
cal by Everson , more than half fall into one of four categories: 
neuroblastoma of adrenal and related tissues, 28; hypernephroma, 21; 
choriocarcinoma, 13; and malignant melanoma, 12. It is pertinent that 
all these tumors arise either in children or in adults younger than 
43 those susceptible to the common malignant diseases. 
Finally, consistent with Burnet's fourth prediction, at least 
10 222 227 four types of malignant tumors (neuroblastoma , thyroid , prostatic 
and cervical carcinomas) are much more frequently diagnosed in random 
pathological specimens than they are found clinically in comparable 
populations. An unavoidable interpretation is that many accumulations 
of malignant cells never progress to overt malignancy, but instead are 
"kept in check" or destroyed by host defense mechanisms. Supporting 
this interpretation is the finding that the intensity of the host cel¬ 
lular response in specimens of a wide variety of malignancies is directly 
correlated with prognosis.26,70,123,193 
Experimental Evidence: 
A wealth of experimental evidence also exists to support the involve 
ment of host defenses, especially thymus-derived lymphocytes (abbreviated 
"T-cells"), in surveillance and destruction of neoplastic cells. Perhaps 
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the best evidence is that derived from studies of tumors induced by both 
DNA and RNA oncogenic viruses in which ablation of thymus-dependent 
functions has been associated with a high incidence of malignancy. 
Thymectomy or anti-lymphocyte serum (ALS) treatment permits the appear¬ 
ance of tumors in mice and rats deliberately or naturally infected with 
the DNA polyoma virus- ^^323,324 purtherm0re, reconstitution with 
tumor-sensitized thymus, spleen or lymph node cells in these immuno¬ 
logic cripples prevents the development of the malignancies."'^84,29^1 
Likewise, susceptibility of mice and rats to oncogenesis by a variety 
of C-type RNA viruses is significantly increased by many immunosuppressive 
procedures, including thymectomy00’ * , irradiationJU , and treat- 
ment with ALS , cortisone , cytoxan or daunomycin. 
While some apparently contradictory evidence exists with thymectomy in 
TOO IOO pifi 
mouse leukemia vi rus-induced tumors ’ 5 , which require the thymic 
1 8? 
microenvironment for tumor progression , overwhelming evidence exists 
to support immune surveillance in experimental virus-induced tumors. 
The interactions of virus, immunity, and malignancy are made some¬ 
what more complex by the fact that most oncogenic viruses are in them¬ 
selves immunosuppressive.^ Thus, oncogenic viruses may: (1) induce 
neoplasia per se, which can then be facilitated by other forms of immuno¬ 
suppression; or (2) cause immunosuppression primarily, making the host 
251 
more susceptible to the neoplastic process. In this context, it is 
interesting that the onset of malignancies induced by Friend leukemia 
virus (FLV) in mice are always preceded by the immunosuppressive effects 
71 
of FLV. 
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Carcinogenic hydrocarbons also suppress host immunity, both hu- 
299 301 1 80 25P 
moral * and cellular * , while noncarcinogeni c hydrocarbons 
299 do not. The evidence for the effects of additional immunosuppression 
on chemical carcinogenesis is somewhat conflicting ; however, thy¬ 
mectomy and/or ALS treatment have usually resulted in an increased 
incidence of tumors, a decreased latency, or both, when animals are 
o/r ~7 o o c 
given chemical carcinogens. ’ 
Other experimental approaches supporting the significance of host 
immunity in defense against malignancy have included: (1) the increased 
incidence of spontaneous tumors in deliberately immunosuppressed animals; 
and (2) the documented immunoincompetence of animals, such as AKR and 
85 205 NZB mice, which have a naturally high incidence of malignancy. ’ 
The Demonstration of Tumor-Specific Transplantation Antigens (TSTA): 
Pivotal to this entire discussion of immunological surveillance 
is the concept that tumors are antigenic. As early as the turn of the 
century the hope was held that dissimilarities between neoplastic and 
normal cells would enable the development of an anti-cancer vaccine, 
and transplantation experiments seemed to show the presence of tumor- 
specific antigens. The field of tumor immunology later fell into 
disrepute when it was recognized that these claims of tumor-speci fi ci ty 
were based on experiments in which immunity to normal alloantigens, 
331 
rather than tumor-specific antigens, had been evoked. 
The demonstration of TSTA awaited the development of highly inbred 
strains of mice which approached homozygosity so closely that individual 
animals could retain skin grafts from others of the same strain (syngeneic 
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animals). Only in syngeneic systems is it possible to analyze the con¬ 
ditions that cause retention or rejection of either normal or neoplastic 
tissues, since in any allogeneic or xenogeneic combination, tumor spe¬ 
cificities may be masked by strain-speci fi c or species-specific antigens. 
112 It was under these conditions that Foley (in 1953) , and later 
261 Prehn and Main , first demonstrated TSTA in methylcholanthrene (MCA)- 
induced tumors of mice. Their experiments showed that otherwise pro¬ 
gressive syngeneic MCA-induced tumors failed to grow if mice challenged 
with tumor cells had been pre-treated with the same tumor cells. Immu¬ 
nization with normal tissue, or other MCA tumors, was not protective. 
By preimmunization, then, these investigators showed that there were 
antigens unique to the tumor. 
Subsequently it has been widely confirmed that specific antigeni¬ 
city accompanies neoplastic transformation of most cells, whether this 
328 251 transformation is spontaneous , or effected by a chemical carcinogen , 
170 237 294 
or oncogenic virus. *■ ’ In addition to in vivo transplantation 
289 
methods , in vitro methods demonstrating TSTA have included membrane 
immunofluorescence'^, colony inhibition tests'^, and various forms of 
37 309 
cellular and humoral cytotoxicity assays. ’ These methods have con¬ 
vincingly demonstrated the presence of tumor-specific antigens in a 
wide variety of animal tumor systems as well as several malignancies in 
man. 
As a rule, TSTA of virus-induced tumors is the same for all tumors 
induced by the same virus, regardless of histologic type or animal 
170 237 294 
species, but differs in tumors induced by different viruses. ’ ’ 
This is true for both DNA and RNA viruses. Recent evidence suggests 
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that polyoma virus tumors have individually unique antigens in addition 
to their common antigens, however. The tumor-specific antigens 
associated with a given virus do not represent virus particles gathered 
at the cell surface, but rather seem to be components of the tumor cell 
distinct from intact virions. 
Conversely, and implicit in the MCA tumor studies above, chemically 
induced neoplasms produce tumor-specific antigens which do not cross 
170 237 294 
react. ’ ’ Thus, in the example cited, preimmunization with 
tumor cells of a different MCA-induced neoplasm did not protect against 
the malignant potential of the original MCA tumor challenge. Exceptions 
234 to this rule have been reported , but in general, TSTA's associated 
with carcinogens are unique for each tumor produced. 
The demonstration of antigenic cross-reactivity between a tumor of 
unknown etiology and a second tumor of known viral causation justifies 
the search for a causative virus in the first tumor, but does not prove 
that they are induced by the same virus. First, a phenomenon known as 
"antigenic conversion" may have occurred, whereby a common tumor antigen 
has been secondarily acquired (e.g., through viral superinfection) by 
the neoplastic cells. Second, activation of genes normally only 
expressed in embryonic states may have occurred, producing "cardnofetal 
antigens. Three such antigens identified in man are: (1) "carcinoembry- 
onic" antigen (CEA), associated primarily, but not exclusively, with 
adenocarcinomas of the digestive tract ; (2) a-fetoprotein, an antigen 
produced by hepatoma cells and some testicular neoplasms'^; and (3) y- 
fetoprotein, a fetal antigen produced by a wide variety of primarily 
89 
malignant tumors. Finally, genes that are normally redundant may have 
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been activated in the transformed cells, as is the case with the TL 
32 
antigens of mouse leukemias. 
Mechanisms of "Escape" from Immunologic Surveillance: 
A common view in the past has been that tumor-specific antigens 
could not possibly exist, since they would result in the immediate im¬ 
munologic recognition and destruction of the cells which carried them. 
The existence of tumors in apparently "normal" individuals, in addition 
to the presence of common lymph node metastases, was taken as prima facie 
evidence for nonantigenicity. Yet, as discussed above, TSTA has been 
clearly demonstrated in almost every tumor system in which its presence 
has been evaluated. Why, then, do some tumors not get rejected? 
At the outset, it is important to state that tumor progression or 
rejection is an extremely complex phenomenon which probably has no single 
explanation. It is perhaps useful to consider host immunity and neo¬ 
plasia as independent components of resulting clinical disease, although 
it will be made clear that this is a somewhat artificial distinction. 
In some instances, presumably independent genetic factors cause 
thymus-dependent immunity to be markedly diminished or absent, allowing 
neoplastic cells to proliferate unchecked. Good's "experiments of 
nature", and malignancies of the very old and the very young, fit most 
easily into this category. 
It has already been suggested that the immunosuppressive nature of 
both viral and chemical oncogens may allow antigenic tumors to develop, 
over and above their abilities to transform cells. 
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Growing tumors, in themselves, may be non-speci fi cal ly immuno¬ 
suppressive, perhaps through elaboration of "factors" that depress 
Q1 14R 174 IQ? ?11 
immunologic reactivity. 5 ’ ’ ’ Notable in this context is 
the significantly increased incidence of second tumors seen with 
Hodgekin's disease and tumors of the head and neck, malignancies often 
211 275 followed by non-specific irrmunosuppression. ’ 
A fourth factor which may contribute to the progression of anti¬ 
genic tumors in vivo is the fact that neoplasms generally develop from 
small foci of cells which may not provide sufficient early antigenic 
stimulation to elicit a vigorous immune reaction, and therefore "sneak 
237 through" host surveillance mechanisms. Some evidence suggests that 
133 these spontaneous tumors are only weakly immunogenic. Other exper¬ 
imental evidence exists that, under certain conditions, this lack of 
immunogeni ci ty may be due to the coating of cells with substances (such 
as sialomucin) which ordinarily prevent recognition. ’ In still 
other situations, specific tolerance to the antigens of the tumor or 
223 inducing virus may occur. 
Once the tumor has developed, progressive growth may be unchecked 
or even accelerated by host-specific inmune mechanisms, a phenomenon 
known as "enhancement". Here, TSTA is recognized by the host, but 
surveillance is blocked by antigen, antibody, or complexes of the two. 
Enhancement may be: (1) afferent, in which TSTA is blocked from stimu¬ 
lating immunocompetent cells of the host; (2) efferent -- either peripheral 
or central -- whereby blocking occurs at the "target" tumor cells or at 
the host's effector cells, in both cases preventing effector cells from 
"seeing" their targets; or (3) central, in which blocking factors regulate 
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or inhibit the production of tumor-specific immune mechanisms, pre¬ 
sumably within lymphoid centers, e,g., lymph nodes and spleen.147,158 
Both in vivo and in vitro studies have shown that enhancement may play 
a significant role in the host-tumor relationship of many experimental 
and human malignancies. A more detailed discussion of enhancement, 
with special emphasis on its significance in human and experimental 
models of osteosarcoma, can be found in the "Discussion" section of 
this presentation. 
Finally, there are some investigators who propose that antigenic 
. . . , r .......... u • 203,259,260,283 tumors persist because of, and not it spite of, host mechanisms. 
259 260 Prehn ’ , in particular, has suggested that small amounts of host 
response may stimulate tumor growth, while a more intensive cellular 
response inhibits it. While this theory has significanct heuristic 
value and may be pertinent to certain tumor systems, there is currently 
259 
no in vitro support for it, and it is otherwise largely untested. 
On the other side of the host-tumor relationship, characteristics 
of the neoplastic cells themselves may override the importance of host 
defenses. For example, i ntrinsi cal ly more aggressive tumors (shorter 
in vitro doubling time), or those that more readily "shed" antigens, may 
grow progressively, the latter presumably through increased blocking 
5 
activity. Tumor cells can also reduce their sensitivity to immunologic 
attack, by both selective (genotypic) and adaptive (phenotypic) mecha¬ 
nisms. These are the processes of "immunoselection" and "antigenic 
, . , 106 ,238 
modulation , respect! vely. 
It is beyond the scope of this paper to comprehensively review all 
of the complex variables involved in the process of tumor rejection or 
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progression. An attempt has been made to show that many factors of both 
host immunity and neoplastic cells require consideration for an insight 
into malignancy, with the understanding that these considerations should 
direct future therapeutic efforts. 
B. The Relationships between Chemotherapy, Immunity and Malignancy 
The complicated interrelationship between oncogens, immunity, and 
malignancy are made even more complex by the addition of chemotherapeutic 
agents. Difficulties are encountered due to the fact that most cancer 
chemotherapeutic agents also cause immunosuppression^05,205,208, and in 
most cases, this effect is due to the very antiproliferative action 
that is at the basis of their anti-tumor activity. Anti cancer drugs 
may inhibit both humoral and cellular responses, usually non-speci fical ly 
but under certain circumstances specifically, and these effects are 
very dependent on drug dose and schedule, type and amount of antigen, 
I nr p op 
and time and route of antigen administration. ’ In addition, drugs 
may act on neoplastic cells by a variety of means to concomitantly 
207 increase their immunogenicity or susceptibility to immune destruction. 
At the preclinical and clinical levels, there is substantial evi¬ 
dence that judiciously used anticancer drugs may act cooperatively, even 
synergistical ly, with immunological defenses directed against primary 
onr 
tumors/ It is important to define the conditions in which this syn¬ 
ergism is most likely to occur, and to utilize this knowledge thera¬ 
peutically. In many cases, however, immunosuppression by chemotherapeutic 
agents is unavoidable. Since most effective cytotoxic drugs may reduce 
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the size of a tumor markedly, but are not selective enough to kill the 
last tumor cells, host tumor-specific mechanisms are required to effect 
a cure. In these cases, the exploitation of sequential chemotherapy 
198 
and immunotherapy seems promising. Thus, chemotherapy-induced immuno¬ 
suppression may be non-specifically or specifically reversed by adjuvants 
such as BCG, or specific tumor-cell vaccines or transfer factor.^7,176 
Before these therapeutic approaches can be successfully used, however, 
much more needs to be learned of the effects of given agents on both 
neoplastic cells and immunologic defenses. 
Effects of Chemotherapy on Neoplastic Cells: 
The direct tumoricidal effect of chemotherapeutic agents is the 
primary mechanism of their anticancer activity, and a vast literature 
supports the rationale for their use in di fferent mali gnancies, and 
under different doses and schedules. That they have in certain malig¬ 
nancies even effected cures is indisputable^’^’^, and these 
examples attest to the significance of their cytotoxic potential. 
In addition, anticancer drugs have been shown to induce increases 
in tumor immunogenicity, and while inadvertent changes may, in part, be 
responsible for their therapeutic efficacy, deliberate changes have been 
induced to enhance host immunologic "efficiency". Basically three 
approaches have altered tumor immunogenicity, directed to: (1) drug- 
induced alterations of cell metabolism possibly leading to plasma membrane 
changes; (2) chemical modifications of the plasma membrane presumably 
providing new haptenic determinants or helper (carrier) functions; and 
(3) enzymatic treatments of cells leading to increased availability of 
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207 
antigenic determinants in the plasma membrane. Fourth, a drug may 
increase the immunogenicity of cells resistant to an anticancer drug 
159 through a phenomenon known as "collateral sensitivity". In this 
discussion, the inadvertant effects of common cytotoxic agents will be 
emphasized, while excellent reviews of deliberate changes in tumor 
159 207 
cell immunogeni ci ty can be found elsewhere. ’ 
Drugs affecting the control of gene action have altered both cell 
metabolism and antigenic expression in a few systems. Particularly 
321 
convincing are studies with steroids used in rat hepatomas , and 
44 5-bromodeoxyuridine in other experimental models. Likewise, 5-fluor- 
ouracil (5-FU) treatment in vivo has caused specific changes in TSTA. 
In this case, however, it was demonstrated that increased tumor cell 
immunogeni ci ty was due to chemical coupling of the drug to antigen or 
haptens on the plasma membrane. 
While the clinical significance of the above effects is not known 
at this time, the importance of collateral sensitivity in particular 
159 207 
malignancies has been well documented. * In one representa ti ve 
29 
study , it was found that the immunogenicity of L1210 leukemias, as 
reflected by transplantabil i ty tests and survival times, was greatly 
increased during the development of resistance to 5-[3,3-dimethyl-1 - 
triazenel-imidazole-4-carboxamide (DTIC). From the eighth transplant 
generation onward, a DTIC-resistant subline could not grow in suscep¬ 
tible CDF-| (DBA/2Cr xBALB/c ) mice, even after the inoculation of 10^ 
cells, unless the animals were treated with immunosuppressive regimens 
of DTIC or cyclophosphamide. The resistant subline was more sensitive 
to treatment with 1,3-bi s [2-chloroethyl 1-1 -ni trosourea (BCNU) than 
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parent LI210. A variety of other reports have also demonstrated that 
the increased chemotherapeutic sensitivity of resistant tumor sublines 
is dependent on the integrity of host defense mechanisms. While some 
reports suggest that the resistant tumor cells are more susceptible 
to host defenses (e.g., via changes of intrinsic growth character!’sties 
343 
of the cells) , the majority of evidence has supported the probabil¬ 
ity that resistant sublines are more immunogenic than the parent cells. 
Effects of Chemotherapy on the Immune Response: 
In addition to chemotherapeutic cytotoxicity and changes in cellu¬ 
lar immunogenicity, most anticancer agents are immunosuppressive in 
animals and man under a variety of conditions. While this immunosup¬ 
pression has been successfully exploited in clinical situations such 
152 208 
as organ transplantation and autoimmune diseases ’ , in cancer 
209 
chemotherapy it is more likely to be counterproductive. 
Immunosuppression by drugs is usually considered nonspecific in 
nature, in that it is the consequence of a pharmacological action, such 
as inhibition of cell prol i feration, which may not uniquely affect 
immunological systems. Yet this is not always so; e.g., an anti-proli¬ 
ferative agent would affect preferentially lymphoid cells stimulated 
as a consequence of antigen exposure without necessarily reducing sub¬ 
sequent capabilities of the immune system to respond to different 
282 
antigens, or el iminating non-proliferating "memory" cells. Thus, 
a specific effect can be obtained by intrinsically nonspecific pharma¬ 
cologic means. The significance of this in cancer chemotherapy will 
207 
be indicated below. 
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As noted in preceding sections, thymus-derived "T-cells" are 
considered the most significant of the host immune mechanisms in defense 
against neoplasia. In addition, lymphoid cells derived from bursa- 
equivalent tissue ("B-cells") and macrophages play roles of definite 
significance in some tumor systems, while being of more equivocal 
import in others. B-cell synthesis of antibody against certain, but 
not all, antigens is triggered as a consequence of an interaction 
between certain types of ("helper") T-cells, B-cells, and macrophages. 
These complex, and incompletely understood, relationships between 
immune cells and their target tumor cells, are represented simply in 
c. , 212 Fi gure 1 . 
Both B and T-cells comprise a series of individual cell types at 
different levels of differentiation. Unique antigenic and functional 
features characterizing these cell types provide the basis for a great 
pop 
variety of cellular responses to drugs. In this context, it is 
likely that certain drugs exert selective effects on specific cells 
depending in large part on their functional and metabolic status. Known 
examples of this specificity include the selective inhibition of B-cell 
21 8 populations by asparaginase , and that of T-cell populations by pro- 
, 104 
carbazene. 
The timing and schedule of drug treatment may likewise be impor¬ 
tant aspects of this cellular sensitivity and selectivity. Indeed, 
cytotoxic agents have been divided into groups according to whether 
they exert optimal immunosuppression when administered before or after 
1 °5 
antigen. " In general, maximum immune depression is obtained when 
drugs are given close to the time of antigen administration, suggesting 
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Killing of 
tumor cells Mediators ("lymphokines") 
(stimulators and inhibitors) 
1) Cytophilie antibody 
2) Blocking Factors 
(antigen-antibody) 
Killing of 
tumor cel 1s 
T = T lymphocyte 
B = B lymphocyte 
M = Macrophage 
Figure 1 
Interaction of lymphocytes and macrophages in tumor destruction. 
Adapted with permission from Mitchell (212). 
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that the early stages of cell differentiation and proliferatiori are 
especially susceptible to inhibition. 
While timing is particularly pertinent to experimental systems, 
drug schedules apply equally well to human therapeutics. In this re¬ 
gard, it would appear that daily treatments with certain drugs suppress 
more T-cell responses than humoral responses, whereas the opposite has 
120 209 been reported to occur with intermittent treatments. ’ That this 
may be of extreme practical importance is the evidence that in certain 
dispersed malignancies, such as leukemia, B-cell functions may inhibit 
213 tumor growth , whereas in solid tumors humoral factors may cause 
enhancement of growth. ^ Clearly, immunosuppression in the former 
instance may be deleterious, whereas it might assist tumor rejection in 
the latter. 
In clinical situations, immunosuppression by a drug may precede 
its other anti -prol i ferati ve actions. In strain-2 guinea pigs, for 
example, established delayed hypersensitivity to tuberculin was inhi¬ 
bited by 2-week treatment with methotrexate at doses which did not 
119 
cause leukopenia, overt lymphotoxicity, or anti-inflammatory effects. 
That unsuspected deleterious immunosuppression may occur has also been 
shown in other preclinical and clinical situations. * ’ The de 
novo occurrence of tumors in immunosuppressed transplant patients is 
certainly one example. Another is the earlier and increased incidence 
of recurrences and death in patients with bronchogenic carcinoma 
treated with long-term cytoxan adjuvant chemotherapy, over patients 
38 
treated for shorter periods, or even left untreated. 
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The evaluation of the interrelationships between drug effects on 
tumor, drug effects on immune reactions to tumor, and the anti-tumor 
effects of tumor-specific immune mechanisms is difficult to achieve 
within a given tumor-host system. Nevertheless, substantial progress 
has been made in the development of model systems designed to sort out 
206 the relative significance of each of these factors, and Mi hi ch has 
established a set of general criteria for relevant investigations. 
209 One such experiment cited by Mihich will be briefly summarized. 
As few as 10 leukemia LI210 cells grow progressively in DBA/2 
mice and in F-| hybrids or backcrosses derived from them. In these 
animals, arabinosylcytosine (AraC) was administered at 10 mg/kg i.p., 
once or twice daily for six days, starting 1,2,3,4 or 5 days after i.p. 
inoculation of 106 L1210 cells. If treatment was begun on days 1 or 2, 
only at the total daily dose of 10 mg/kg did AraC induce the expected 
50% incidence of 50-day cures, whereas there were no cures seen at 
20 mg/kg total daily dose. If treatment was started on day 5, only 
at the total daily dose of 20 mg/kg did AraC induce a 60% incidence of 
cures, no cures being seen at the lower daily dose. Consistent with 
this, total-body irradiation prevented the curative effects of AraC 
(at 10 mg/kg for six days from day 1) when given on days 1, 2 or 3, 
but not when given on days 4 or 5. 
These data indicate that shortly after antigenic stimulation, in 
the presence of few leukemia cells, the low dose of AraC was sufficient 
to eradicate the leukemia without affecting the imnunological response 
of the host. In contrast, high doses of AraC were immunosuppressive 
under these conditions, preventing host-dependent defenses from becoming 
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evident. Conversely, when treatment was started late after antigenic 
stimulation (in the presence of many leukemia cells), the low doses 
of drug were insufficient to eradicate the leukemia, whereas high doses 
were chemotherapeutic, being less suppressive to the now ongoing immune 
response. Additional support using L1210/AraC cells (a subline resis¬ 
tant to AraC) suggested that this subline would not regress unless 
rejected by cross-reacting immunity elicited by LI210 during drug 
treatment. 
It is important to note that some evidence exists that pre-existing 
active immunity is usually not severely affected by anti cancer drugs 
at therapeutic doses, and that recovery of responsiveness may occur 
190 90£ 
as early as three days after the end of treatment. ’ In addition, 
reports have documented that 6-mercaptopurine, a purine anti-metaboli te, 
341 342 
may actually enhance antibody formation in certain situations. ’ 
However, as noted above, it is clear that most anticancer drugs, in 
addition to their tumoricidal actions, may exert immunosuppressive, and 
possibly "immunosynergistic" effects depending on the conditions in 
which they are used. As pointed out by Mihich, "the preservation of 
immune reactivity during treatment with anticancer drugs is undoubtedly 
as important a goal as is, for example, avoiding gastrointestinal or 
209 bone-marrow toxicity". That such considerations are under-emphasized 
in clinical medicine is, in part, a reflection of the lack of available 
methodologies in the past to evaluate drug effects on tumor-related 
immune mechanisms, and the present paucity of such knowledge relative 
to specific drugs. In the future, cancer chemotherapeutics may be 
aided by the knowledge that given drugs are immunosynergistic when used 
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under speci fied conditions. Where immunosuppression is unavoidable, 
as noted earlier, efforts are being made at approaches directed to 
reversal of that imnunosuppression^^ in order to maximize the 
host-drug attack on neoplastic cells. 
C. Adriamycin 
Chemistry and Mode of Action: 
Adriamycin is an antibiotic of the antracycline group first iso- 
1 5 lated in 1 969 from cultures of Streptomyces peucetius var. caesius. 
Its chemical structure resembles that of daunomycin, differing only in 
the substitution of a hydroxyl group for a hydrogen atom in the acetyl 
radical of the aglycon portion of the molecule. 
The biological activity of adriamycin at the cellular level is 
thought to be related to its ability to bind specifically with DNA by 
intercalation between adjacent base pairs of the double-helical 
84 338 
structure. ’ By subsequently inducing stereochemical template dis¬ 
ordering, enzymes involved in both transcription (DNA-dependent RNA- 
polymerase) and DNA replication (DNA-dependent DNA-polymerase) are 
nor 
inhibited. These effects are consistent with the in vivo and cell 
culture data showing the inhibition of incorporation of precursors into 
DNA and RNA, inhibition of mitosis, and induction of chromosomal aber¬ 
rations. All are thought to represent the basis of adriamycin's sig- 
... , ... .. .. 80,204,326 
mficant antitumor activity. 
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Pharmacol ogy: 
The distribution and metabolism of adriamycin have been studied 
16 78 336 
using tritium-labelling as well as fluorescence techniques. ’ ’ 
It is rapidly cleared from the blood, and in rodents, high drug levels 
are maintained for a long period of time in the liver, spleen, kidney, 
lung, and heart. ’ The calculated C x t (concentration x time) 
for adriamycin equivalents in all tissues has been demonstrated to be 
several times greater than that found for daunomycin or its metabolites 
In man, adriamycin has a distribution comparable to that seen in 
rodents, and in both species the drug shows negligible ability to 
on o 
penetrate the blood-brain barrier/ ’ Urinary excretion is minimal, 
with only 5% of the drug being excreted during the first five days. 
Adriamycin is metabolized predominantly by the liver to adriamycinol 
and several aglycone derivatives, and approximately half of the drug 
is excreted in the bile as adriamycin, another 30% being excreted as 
21 its conjugates. Prolonged plasma levels of adriamycin in patients 
with hepatic dysfunction provide the basis of a requirement for dose 
20 deescalation in patients with impaired hepatic function. 
Antiviral Activity: 
The antiviral activity of adriamycin has not been as extensively 
evaluated as that of its closely related analogue, daunomycin, but 
both drugs have been shown to be inhibitory against a variety of DNA 
and RNA bacterial and animal viruses. Inhibition of bacteriophage 
multiplication by daunomycin has been reported by a few investiga- 
244 278 tors ’ , and this drug protects cells from herpes simplex virus 
336 
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when given before or a few hours after infection, whereas no effect was 
demonstrable when the drug was added four hours after infection, when 
83 
the mature virions are thought to appear. 
Significantly, both daunomycin and adriamycin added to the incuba¬ 
tion medium at different times before and after infection inhibit the 
multiplication of Moloney sarcoma virus (MSV) and the focus formation 
46 typical of this virus in mouse embryonal cells. It has been demon¬ 
strated that both drugs also inhibit the reverse transcriptase activity 
49 
of RNA tumor viruses. The concentrations active on these processes 
have negligible effect on cellular proli feration 
Clinical Experience: 
Since 1969, well over 3,000 patients have been treated with adria¬ 
mycin alone or in combination with other chemotherapeutic agents for 
4 
virtually all types of malignancy. Its activity is wide-ranging, 
being most effective against solid tumors but also active against the 
hematologic malignancies. Ten forms of cancer have been treated effec- 
99 tively with adriamycin: breast cancer, soft-tissue and osteogenic 
sarcomas, cancers of the bladder, lung, thyroid and ovary, Wilm's tumor, 
neuroblastoma, Hodgekin's and non-Hodgekin's lymphomas, and acute 
leukemias. The particularly striking efficacy of adriamycin against 
osteosarcoma is described in more detail in a later section. 
Tumors with encouraging, but more equivocal responses than the 
above, include cancers of the stomach, prostate, liver, head and neck, 
and multiple myeloma. The drug has apparently no role in the treatment 
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of adenocarcinoma of the large bowel, malignant melanoma and kidney 
99 
cancer. Excellent reviews of the current clinical experience with 
4 99 232 
adriamycin can be found elsewhere. ’ ’ 
Animal Tumor Studies: 
A substantial number of studies have shown adriamycin to be effec¬ 
tive in delaying tumor progression and increasing survival times in a 
14 25 45 79 81 
variety of transplanted and primary experimental tumors. ’ * * ' * 
32 277 
’ Its efficacy and toxicity vary greatly with timing, dose, 
25 45 79 
schedule and route of administration. ’ ’ 
Adriamycin is highly active in inhibiting the growth of trans¬ 
planted Ehrlich acsites tumors in mice, where its effect on increasing 
survival times was significantly greater than that of daunomycin. 
Likewise, adriamycin proved superior to daunomycin in inhibiting the 
79 growth of transplanted sarcoma 180 tumors in mice. These data support 
the higher therapeutic index and generally greater antitumor activity 
of adriamycin as compared to daunomycin, especially against solid 
79 tumors, in experimental systems. 
Of special interest is the striking efficacy of adriamycin on 
spontaneous mammary carcinoma of C3H mice, an autochthonous tumor highly 
resistant to most chemotherapeutic agents. Treatment started the 
day after tumor implant and repeated every second day for two subse¬ 
quent cycles strongly inhibited tumor growth and produced a highly 
significant increase in survival time. Treatment with identical doses 
administered on consecutive days, however, simply caused a delay in 
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tumor development, without increase in survival time over control 
79 
animals, and, interestingly an increase in metastatic dissemination. * 
Toxicity and Effect on Immunity: 
In man, toxic effects induced by adriamycin are dose-related pre¬ 
dictable, and usually reversible. The most frequent side effects are 
dose-limiting myelosuppressi on, mucositis, nausea, vomiting, and 
4 
chemical phlebitis. 
Leukopenia is the primary hematologic toxicity, occurring in over 
60% of patients, with a nadir occurring between days 10 and 14. Throm¬ 
bocytopenia and anemia likewise occur during this period but their 
occurrence is generally less frequent and less severe. Peripheral 
counts usually return to normal by day 21. 
Severe mucositis, which limit the administration of adriamycin, 
appears to be schedule-dependent. 
Another unusual and dose-limiting side effect is cardiotoxi ci ty. 
This may involve transient EKG abnormalities or serious irreversible 
drug-induced cardiomyopathy. Analyses by Le Frak et al. show a 
frequency of non-fatal and fatal cardiomyopathy of 0.4% and 1.2%, re¬ 
spectively. The incidence of cardiomyopathy is dose-dependent, being 
2 
markedly increased at total drug doses above 550 mg/m . The measure¬ 
ment of systolic time interval in patients approaching this dose may be 
272 
a sensitive indicator of impending cardi otoxi ci ty. 
There are a few reported studies in animal systems indicating that 
82 
adriamycin may have immunosuppressive effects at certain doses and 
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45 79 151 241 ?R1 
schedules of administration. * * * * These studies can be 
broken down as showing effects on either general immune function or 
tumor-specific host defenses. 
161 Isetta et al. reported that adriamycin significantly inhibited 
the titer of hemolytic and hemagglutinating antibodies in mice immunized 
with sheep red blood cells. These effects were dose-related and were 
highest soon after antigen administration. Likewise, antiviral anti- 
45 bodies responses were abolished by adriamycin in another animal system. 
No data are yet available regarding the effect of adriamycin on general 
cel 1-mediated immune functions. 
At least four reports to date indicate that adriamycin may inhi¬ 
bit tumor-specific host mechanisms, and that this inhibition may be 
45 7Q ?4l ?ftl less than that caused by daunomycin. ’ ’ * 
As noted earlier, daily doses of adriamycin to C3H mice bearing 
mammary carcinomas caused no increase in average survival time (AST), 
and, in fact were associated with a significantly increased incidence 
of metastatic dissemination in these animals. That this was perhaps 
due to immunosuppression is the evidence for the cumulative toxicity 
79 
of adriamycin when administered daily as well as the data suggesting 
that T-cell functions may be preferentially depressed with this drug 
, , , 120,209 
schedule. 
A study more pertinent to the present investigation involved the 
effects of daunomycin and adriamycin on the growth and regression of 
primary or transplantable murine sarcoma virus (Moloney)-induced tumors 
45 in CD-I mice. The experimental design, as discussed more fully in a 
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later section, is based on the observation that tumors induced by low 
viral titers regress spontaneously in 90% of the animals. Thus, adri¬ 
amycin's chemotherapeutic activity, as well as its effects on the 
mechanisms of spontaneous tumor regression, can be evaluated in this 
system. 
Treatment with daunomycin before infection inhibited spontaneous 
tumor regression, whereas pretreatment with adriamycin caused a delay 
and inhibition of tumor growth and no effect in tumor regression as 
compared to controls. Treatment with daunomycin after the infection 
(i.v. for eight consecutive days) caused a slight reduction of tumor 
size as compared to controls, and a high incidence of tumor recurrence. 
Adriamycin treatment after the infection caused a greater reduction on 
tumor size than with daunomycin, and tumor recurrence took place later 
in time. 
While no in vitro tests of tumor-specific cellular or humoral 
immunity accompanied these data, they demonstrate that both antibiotics, 
in the schedules used, have tumor-related immunodepressive activity. 
In addition, the results suggest that adriamycin is probably less immu¬ 
nosuppressive and/or more tumoricidal in this system than is daunomycin. 
241 In pursuing these possibilities, Orsini and Mihich confirmed 
the therapeutic advantage of adriamycin in C57B1/6J mice bearing a 
syngeneic EL4 lymphoma. In addition, the immunosuppressive effects 
of the drugs were compared in two different systems using in vitro 
tests measuring cellular and humoral cytotoxicity. While neither system 
measured responses to syngeneic tumor - sped fi c antigens, both systems 
revealed the drugs to have selective effects, under certain conditions, 
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on cellular immunity. These imnunosuppressive effects were apparently 
less than those caused by AraC or methotrexate in the same systems. 
In contrast to their expectation, no significant differences between 
the effects of adriamycin and daunomycin were seen in the systems used. 
No studies to date have reported the effects of adriamycin on 
general or tumor-specific immunity in man. While some evidence exists 
in animals, it is not yet clear under what conditions its primary effect 
may be on humoral^or cellular^’^’^ immunity. Finally, no 
in vitro data have been obtained supporting the suggestion from in vivo 
studies that adriamycin suppresses tumor-specific host immunity. 
D. Osteosarcoma in Man 
The term "osteogenic sarcoma" has been variously used by different 
authors as the generic name encompassing all primary bone tumors of 
mesenchymal origin, or as a specific malignant osteoid-producing entity 
originating in endosteal bone. This distinction is an important one, 
since the several entities included in the former classification have 
different biologic behaviors, and carry with them unique diagnostic, 
therapeutic, and prognostic implications. Although the more restricted 
use of the term will be employed herein, the literature is replete 
with references employing the generic usage (or more confusing modifi¬ 
cations), thus necessitating a brief description of the various entities 
from which true osteosarcoma should be differentiated. 
The principles outlined for the generic usage of "osteogenic 
39 194 
sarcoma" were first described by Budd and MacDonald ’ and later 
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201 
refined and expanded by McKenna et al. Predicated on their belief 
that sarcomata arising in connective tissue of bone "have as their 
anlage the stem mesenchymal cell which may differentiate toward fibrous 
tissue, cartilage or bone", Budd and MacDonald subdivided osteogenic 
sarcoma into three primary categories: fibrosarcoma, chondrosarcoma, 
and osteosarcoma, respectively. McKenna et al. also included as osteo¬ 
genic sarcoma those bone-producing malignancies arising in Paget's 
disease and areas of fibrous dysplasia, tumors induced by prior irra¬ 
diation, and parosteal (juxtacortical) osteogenic sarcomata. 
Defined microscopically, chondrosarcoma is a tumor in which the 
dominant cell type assumes a cartilaginous histopathological differen¬ 
tiation. Classification of these tumors according to degree of ana¬ 
plasia reveals a distinct correlation with five-year survival rates, 
78% of persons with lowgrade anaplastic tumors and 22% of person with 
201 highgrade malignancies living for five years. 
Clinically, the patient with a chondrosarcoma is likely to be in 
his fourth decade, and three times more likely than the patient with 
osteosarcoma to have his primary lesion in the pelvis, jaws, ribs, or 
scapulae. Although the duration of symptoms before treatment may be 
somewhat longer than that in osteosarcoma, presenting symptoms and 
laboratory findings at diagnosis are substantially very similar. Meta¬ 
static disease localizes in a likewise similar manner, although chondro¬ 
sarcoma is a fundamentally less virulent malignancy than osteosarcoma, 
and there is much less tendency to early metastasisAmputation is 
the therapeutic mainstay, and five-year survivals in several series 
. , ,, . . -... . 69,201 ,239 
are consistently about fifty per cent. 
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Fibrosarcoma is that malignant tumor of endosteal bone composed 
of predominantly interdigitating bundles of spindle-shaped fibroblastic 
cells, including varying amounts of collagen. It is usually subdivided 
162 201 
according to its degree of anaplasia , but according to McKenna et al. 
this grading reveals no correlation with survival. These tumors 
contain no osteoid; however, the dense collagen of some fibrosarcomata 
is so similar to osteoid as to make the differentiation from fibro- 
298 blastic osteosarcoma one of great difficulty. 
The incidence of fibrosarcoma is approximately one-fourth that of 
201 
osteosarcoma, and the typical patient is in his fourth decade. The 
location of the primary tumor, its pattern of metastasis, as well as 
other clinical parameters are often similar to osteosarcoma. Fibro¬ 
sarcoma generally follows a less aggressive course, however, and five- 
year survivals following amputation are reported as about 30 per cent.00’^0"* 
Perhaps the most common entity to be included in statistics per¬ 
taining to osteosarcoma is osteogenic sarcoma arising in Paget's 
disease. This form of sarcoma may microscopi¬ 
cally resemble classic osteosarcoma, or may be classified as a chon¬ 
drosarcoma or fibrosarcoma.^00 
In addition to its pathological variation, Paget's sarcoma is 
clinically quite dissimilar from osteosarcoma. The median age at diag- 
201 
nosis of Paget's sarcoma is 60 years , and the site of the primary 
tumor is much more likely to be the ileum, humerus or skull than in 
osteosarcoma. Longterm survival is rare: all 11 patients of 
308 201 Sweetnam and all 32 patients of McKenna et al. were dead by five 
years. 
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Radiation-induced sarcomata are pathologically usually either 
201 
osteosarcoma or fibrosarcoma. Strictly defined, these are micro¬ 
scopically proven sarcomata having arisen in a previously normal bone 
five or more years after its having received at least 3000 rads irra- 
r o 
diation. Clinically, the patient population is, as expected, quite 
heterogeneous, antecedent irradiation being performed for a multiplicity 
of malignant, and some benign, conditions. Five-year survivals are 
somewhat better than osteosarcoma arising "de novo" in bone: data from 
. 201 50 years experience at Memorial Hospital in New York suggest that 
after amputation, or amputation plus irradiation, five year survivals 
approximate 40 per cent. 
Sarcomata arising in areas of fibrous dysplasia are unusual, and 
may pathologically be defined as chondrosarcoma, fibrosarcoma or 
1 ro 
osteosarcoma. Because of their rare occurrence, they are seldom 
included in reports of osteosarcoma, and therefore will not be further 
considered here. 
The last important, and often confused, entity to be differenti¬ 
ated from osteosarcoma is the ossifying parosteal sarcoma (juxtacorti- 
cal osteogenic sarcoma). Occurring predominantly during the fourth 
decade and more commonly in women, these bone-forming tumors develop 
on the surface of the bone rather than its interior. They are charac¬ 
terized by an indolent growth rate, "pseudoencapsulation", and apparent 
growth by longitudinal and ci rcumferenti al extension, resulting in a 
201 large tumor mass encircling, or partially encircling the bone. 
In addition to age and sex difference between patients with 
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osteosarcoma and parosteal sarcoma, the biologic courses of the tumors 
are dissimilar. Parosteal sarcoma is substantially less aggressive, 
201 
and metastases, when they occur, are often to the bone. Cure rate 
ICO 
is high : McKenna et al. cite 82% five-year survivors, and a "theo- 
201 
retical curability" of 100%. Nevertheless, cases of parosteal sar- 
I r n 
coma are still often included in series of "osteogenic sarcoma" , 
and their inclusion only serves to confuse and skew statistics meant 
to represent responses of classic osteosarcoma to newer therapeutic 
modalities. 
In differentiation from the above, osteosarcoma in its more re¬ 
stricted usage is a distinct pathological and clinical entity occurring 
mainly in the second and third decades of life, and rapidly progressive 
in most cases, with pulmonary metastases and death within two to three 
years from diagnosis. 
Pathology: 
In general, osteosarcoma may be defined as a specialized connective 
tissue sarcoma which elaborates neoplastic osteoid from an endosteal 
location during the course of its evolution. Most often, the osseous 
tissue arises directly from the sarcomatous connective tissue, but in 
rapidly growing areas it may be formed via a cartilaginous intermediary 
"I C. A 
stage. Histologically, osteosarcoma is remarkable for its varied 
appearance: its microscopic pattern varies considerably from lesion to 
lesion and from area to area within the same lesion, depending primarily 
162 
on the age of the lesion and its degree of osteogenesis. Relative 
to this latter feature, the tumor may be defined radiologically and 
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histologically as either predominantly osteolytic or sclerosing (osteo¬ 
blastic) in type. In the former category there may be abundant amounts 
of either neoplastic cartilage or fibrous stroma, thus justifying its 
histologic subdivision into chondrobl asti c or fibroblastic osteosarcoma, 
. . , 68 
respecti vely. 
Within non-ossified tissue, the cells may be predominantly anaplas¬ 
tic, spindle-shaped or round, the latter in lacunae suggesting cartilage 
cells. In ossified areas, there is relatively orderly histologic pro¬ 
gression according to the age and virulence of the tumor. This is well 
162 described by Jaffe. Initially localized to the interior of the 
affected bone, the originally pleomorphic tumor cells progressively 
spread out from one another, deposit increasing amounts of intercellu¬ 
lar fibrillar collagenous material, and later osteoid and calcium, 
249 
while the cells become progressively more "normal appearing". Pro¬ 
gressive growth of the tumor causes periosteal irritation and subperio¬ 
steal new bone formation, later distending the periosteum (causing 
"Codman's triangle" on radiographs), and finally disrupting and extend¬ 
ing beyond the cortex. 
I nci dence: 
Osteosarcoma is the most common of the primary malignant tumors of 
155 162 bone. 5 There is a definite male predominance, cited variously 
201 162 from 1.4:1 to 2:1 . Its peak incidence is in the second and third 
decades, as about 75% of all patients in any representative series are 
between the ages of 10 and 25 years, with few cases below age 5 and 
fewer still above age 40. Vigorous pursuit of pre-existing bone disease 
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(e.g., Paget's disease) or prior irradiation should be considered before 
accepting the diagnosis of de novo osteosarcoma in any person over 50 
, 162 years of age. 
Localization: 
6 8 In any large representative series, between half and four- 
fifths^ * 6 of the primary tumors are located in the long bones at the 
knee joint. Most of these are at the distal end of the femur, with a 
smaller but significant number originating in the proximal tibia. A 
significant number of primaries are also localized to the proximal 
humerous and femur, and a fair number are first diagnosed in the pelvic 
bones. There appear to be no absolutely privileged sites, but the spine 
and skull bones are rarely involved in the absence of previous irradia¬ 
tion or pre-existing osteitis deformans. 
Clinical Manifestations: 
Persistent local pain without other complaints, is the initial 
symptom in approximately three-fourths of patients with osteosarcoma, 
while swelling, pathological fracture, or local warmth are presenting 
symptoms in a fewer number. Some patients may complain of anorexia, 
weight loss, and rarely, dyspnea or fever, but these are usually late 
symptoms. The average duration of symptoms before seeking treatment is 
usually three to four months.^ 
Of the initial laboratory determinations, only an elevated level 
of alkaline phosphatase is helpful diagnostically, although only approx¬ 
imately one-fourth of patients reveal this abnormality, and then to only 
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2 36 two or three times the upper limits of normal. In these patients, 
levels usually return to normal after definitive treatment, and subse¬ 
quent elevations are a sensitive index of local recurrence or metasta- 
162 
tic disease. 
Radiographically, osteosarcoma presents a variable appearance, 
and its differential roentgen diagnosis is of little more than academic 
interest, in that histological confirmation is required for definitive 
diagnosis. Experienced radiologists can normally predict whether a 
201 bone tumor is benign or malignant in approximately 75% of cases , 
and maximum effort should be devoted to making this distinction, and to 
determining the best site for biopsy. "Codman's triangles", often con¬ 
sidered as diagnostic of osteosarcoma, are encountered in both benign 
and malignant tumors, as well as in non-neoplastic conditions. Like¬ 
wise, lamellated "onion-skin" or speculated "sunburst" periosteal ap¬ 
pearances are not pathognomonic for osteosarcoma, although they carry 
242 
a high correlation with malignancy. 
Clinical Course: 
The typical course of osteosarcoma, treated or untreated, is a 
rapid and relentless one, progressing to pulmonary metastases and 
death within two years of its diagnosis. Indeed, its course is so 
aggressive and predictable that Reinberg in 1960 felt justification for 
saying that "a case of any age that has recovered from osteogenic 
339 
sarcoma has to be regarded as a diagnostic error". 
A comprehensive review of the literature on over 1400 patients 
with osteosarcoma reveals actual five-year survivals, regardless of 

-37- 
primary therapy (operation, radiotherapy, or a combination of the two, 
with or without chemotherapy), ranging from 5 to 25.5%.^^,118,236 
308 pointed out by Sweetnam et al . , however, the proportion of patients 
surviving five years is a relatively uninformative measure, as survival 
curves clearly indicate that mortality is concentrated in the first two 
years from starting treatment, and that thereafter the curves flatten 
out. This is reflected in a typical median survival time of about 16 
.. 308 
months. 
A definitive prognostic and therapeutic point in the course of 
118 
osteosarcoma is the onset of pulmonary metastases. The average time 
201 from onset of symptoms to treatment is about four months , and the 
mean interval from starting radiotherapy, radical surgery, or a combi- 
nation of the two, to pulmonary metastases, is 10 months^ ’ 5 (median, 
less than five months^0). Death, usually from respiratory failure, 
is imminent thereafter, the average period between the discovery of 
236 308 pulmonary metastases and death being consistently six to seven months ’ 
o o/r 
(median, six months ). It is assumed that probably all patients when 
first seen have hematogenously disseminated microscopic metastatic 
248 201 disease , and McKenna et al . describe symptomatic pulmonary meta¬ 
stases in 10% of patients at initial presentation. Autopsy data reveal 
201 
more than 95% of cases with pulmonary metastases. 
Only two large series have systematically evaluated their autopsied 
patients, and these are somewhat confused by the inclusion of some non- 
osteosarcoma bone tumors. ’ Summarized, the metastatic patterns 
are as follows: bone (osteosarcoma only), 14%; lymph nodes, 30-40%; 
pleura, 30%; pericardium, 20%; diaphragm, 18%; kidney, 12%; liver, 
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pancreas and dura, each 8%; adrenal, 6%; thyroid, 4%; and ovary, 2%. 
Local recurrences of tumor were found in 50%, and tumor venous thrombi 
were found in 14 per cent. 
Prognosti c Factors: 
Much effort has been devoted to the determination of factors re- 
284 lated to prognosis in osteosarcoma. Schwinn and McKenna break down 
the several variables discussed into four categories: those with defi¬ 
nite, probable, equivocal, and no discernible correlation with progno¬ 
sis. The following is a brief update and modification of their findings. 
Their first two factors definitely correlating with survival have 
already been discussed. Osteosarcoma has a significantly worse progno¬ 
sis than chondrosarcoma, fibrosarcoma, or parosteal sarcoma, and a much 
better prognosis than Pagetoid sarcoma. 
Relative to location, the rare facio-maxi 1 lary primaries have a 
better survival rate than osteosarcoma arising elsewhere, and, in 
general, those arising in the axial skeleton show worse therapeutic 
results than those tumors more distal to the axial skeleton.^8*201 ,2o4 
Of the latter, tumors in the distal femur have greater curability than 
those in the tibia.^ 
Not surprisingly, a fourth definite correlate with survival was 
stage of disease, persons with metastases to lungs or lymph nodes faring 
much more poorly than those with localized diseases. 
A final significant "prognostic factor" defined by Schwinn and 

-39- 
McKenna is therapeutic intervention -- in their series, persons treated 
by immediate amputation, or radiotherapy followed by amputation, sur- 
284 
vived longer than those receiving no treatment. 
Of the factors identified as "probably" correlated to survival, 
the most interesting is the duration of symptoms. This has been described 
48 ?01 in at least two previous large series ’ -- patients with a short 
interval between onset of symptoms and diagnosis have a worse prognosis 
than do those with a longer interval. It has been suggested that this 
finding supports the involvement of host immunity in those patients 
118 
with a more lingering, indolent prodrome. 
The size of the tumor at diagnosis also probably correlates with 
survival, as a large tumor, other factors being equal, is a bad prog- 
201 284 236 
nostic sign/ ’ This, however, has recently been contested/ 
Factors with an equivocal effect on prognosis include: (1) histo¬ 
logical grade -- using Broder's criteria for grading the histological 
malignancy of the tumor, most Grade I and II tumors (least malignant 
appearing) may have a better prognosis, but these grades are very in- 
68 frequently found. Relative to histological subtype, osteoblastic, 
fibroblastic, and chondroblastic tumors all have similar biologic be- 
haviors;0 5 ’ (2) sex of the patient -- some reports suggest a 
1 13 2 84 better prognosis for females 5 , but this has generally not been 
substantiated; (3) pathological fracture at the tumor site; and 
(4) pre- and post-operative serum alkaline phosphatase levels. 
Factors reported by Schwinn and McKenna to show no correlation 
with survival include: (1) age and (2) antecedent trauma. The former 
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factor cannot be dismissed easily, however, as a recent careful study by 
Ohno and associates^ found age to be the only significant prognostic 
variable of ten parameters studied. In this study, patients fifteen 
years of age or younger fared significantly worse than did the older 
patients. 
Treatment: 
As previously pointed out, actual five-year survivals for osteo¬ 
sarcoma, regardless of primary therapy, have varied from 5 to 25.5 
. 61 ,118,236 per cent. 
The results of radical surgery, the usual form of primary therapy, 
196 have shown no change from 1946 to 1970. Despite differences in pre- 
therapeutic workup, surgical techniques and demography, a comprehensive 
review of 1337 patients treated surgically since 1945 has shown consis- 
tent five year survivals of approximately 20 per cent. Of 438 pa¬ 
tients evaluable at 10 years, 16% were still alive, indicating that the 
majority of those patients living five years appear to be "cured". The 
large surgical literature on osteosarcoma and its consistent findings 
of about one of five patients surviving five years, justifies using 
surgical therapy as the standard against which other therapeutic modali¬ 
ties must be compared. 
The data for radiation therapy alone are difficult to evaluate, 
but they seem to indicate that irradiation is the least effective 
primary therapy of osteosarcoma. A fairly extensive literature suggests 
that the overall five-year survival after radiation therapy alone is 
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118 12.5 per cent. Several factors complicate the interpretation of this 
response rate; patients with metastatic disease at presentation are 
usually considered ineligible for surgery; patients with primaries in 
unresectable locations (possibly secondary to Paget's disease) may have 
more virulent malignancies^’^ ; some patients may have had other sig¬ 
nificant medi cal illnesses mitigating against surgery; and finally, true 
118 tumorical doses (6000-12000 total rads) were not utilized in all patients. 
A combination of therapeutic modalities has enjoyed increasing and 
justified popularity in a variety of malignancies, and osteosarcoma is 
no exception. As noted previously, the onset of pulmonary metastases 
marks a definitive point in therapy, the majority of patients revealing 
clinical evidence of pulmonary disease within five to nine months of 
operation6^’^6, and metastatic disease invariably signifying imminent 
229 308 death. ’ With this in mind, recent efforts in the treatment of 
osteosarcoma have been directed towards two ends: the prevention of 
metastatic disease after surgery, and the attack of overt pulmonary 
metastases. 
The approaches to overt pulmonary metastases have been both sur¬ 
gical and chemotherapeutic. Chemotherapeutic approaches have involved 
both the systemic administration and local infusion of cytotoxic drugs. 
Surgical resection of isolated pulmonary metastases has resulted 
in sporadic instances of prolonged survival, but the overall results 
o op: 
have not been encouraging. Workers in Japan have investigated the 
use of bronchial artery infusions of cytotoxic agents for overt meta- 
235 
stases with encouraging, but not statistically significant results. 
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There had been relatively few attempts at systemic chemotherapy for 
metastatic disease in osteosarcoma until the last few years. Neverthe¬ 
less, with the two exceptions of adriamycin and methotrexate (to be 
discussed in the following pages), metastatic osteosarcoma has retained 
its reputation as a malignancy resistant to traditional chemotherapeutic 
agents. 
Historically, the alkalating agents had been most intensively in¬ 
vestigated, although the numbers of patients were usually small, and a 
variety of schedules and doses were not generally employed. Sporadic 
reports have documented partial responses with systemic cyclophospha- 
mide^>252,300 and phenylalanine mustard^# Overall response 
rates with cyclophosphamide were reported as 14.2% (4/23), and with 
phenylalanine mustard, 15.5 per cent (5/32). 
Mitomycin C was shown to cause regression of pulmonary metastases 
96 114 in 1961 ’ , but the original enthusiasm for this agent dwindled by 
47 304 1971 ’ . Overall, of 76 patients treated, there were 11 responses, 
118 for a response rate of 14.4 per cent. 
The activity of the vinca alkaloids has been likewise disappoint- 
ing, vincristine having shown no responses in 21 cases. Other 
agents used with either low response rates or very small numbers to 
evaluate include 5-fluorouraci 1 , hydroxyurea, procarbazine, and diethyl 
*| I O 1^4 QQ4 
triazene imidazole carboxamide. ’ ’ Little or no data are 
available on the use of many of the alkalating agents, antimetabolites 
118 
or nitrosourea drugs. 
Against this background of minimally promising activity of chemotherapy 
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against metastatic disease are the strikingly more effective results 
obtained with two drugs, methotrexate and adriamycin. The former, when 
given in high doses and followed by citrovorum factor rescue, has caused 
tumor regression in four of ten patients with metastatic osteosarcoma 
I r o 
followed from one to more than eight months. At the time of publi¬ 
cation, complete regression of pulmonary metastases had occurred in two 
patients, and persisted in one of these. In contrast, methotrexate 
r q O 1 Q 
alone or in conventional doses has failed to show any response. ’ 
Finally, Cortes et_al_.60 have reported objective regression of 
pulmonary metastases in 7 of 17 patients treated with adriamycin and 
followed from 4 to more than 20 months. Metastases shrinkage of over 
50% was seen in five patients, and in one there was a complete remission 
Although all patients treated showed signs of toxicity and two patients 
succumbed to adriamycin-associated cardiomyopathy, the data clearly 
revealed the effectiveness of adriamycin in treating metastatic disease, 
and stimulated research into the use of adriamycin as an adjuvant to 
surgery in the prevention of metastases. 
Adjuvant chemotherapy is the most promising of the several methods 
used to approach the second, and more important problem in the treat¬ 
ment of osteosarcoma -- the prevention of metastatic disease. Consider¬ 
ing that hematogenous pulmonary metastases are present in the majority 
35 164 
of patients at the time of diagnosis ’ , three other approaches 
have also been tried, including the pre-operative ligation of the veins 
1 75 57 231 draining the tumor site , prophylactic irradiation of the lungs ’ 
296 
and immunotherapy. The significant roles of tumor immunity and 
immunotherapy in osteosarcoma will be discussed in a later section. 
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While the pre-operative ligation of the veins draining the tumor 
site has not resulted in significantly prolonged survival or fewer 
35 post-operative metastases , there have been many proponents of pro¬ 
phylactic pulmonary irradiation in addition to amputation. These have 
included both pre- and post-operative radiation, at varying intervals 
from surgery, and with varying doses of irradiation. Most reports 
indicate only a slight advantage for the addition of radiation to ampu- 
11 o 
tation. Nevertheless, at least one promising report, showing delayed 
onset of pulmonary metastases after pre-operative radiation plus ampu- 
231 tation, suggests that this is one modality to be pursued further. 
Finally, two chemotherapeutic approaches, one using high dose 
methotrexate with citrovorum factor rescue, and the second using adria- 
mycin, have shown strikingly effective activity in the prevention of 
pulmonary metastases. Their use as adjuvants is based on substantial 
experimental cytokinetic evidence that the proportion of neoplastic 
cells destroyed by a given treatment should be significantly greater 
281 in micrometastases than in clinically apparent metastatic disease. 
In the first chemotherapeutic method, high doses of methotrexate 
are given in conjunction with vincristine, followed two hours later by 
164 12 intravenous doses of citrovorum factor "rescue". This regimen, 
using increasing doses of methotrexate given every three weeks, signi¬ 
ficantly reduced the post-operative incidence of pulmonary metastases. 
Although only 12 of the 20 patients studied had "classic" osteosarcoma, 
11 of these were free of metastases from 6 to 27 months. 
In the adriamycin regimen, six three-day courses (30 mg per square 
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meter daily) were administered (following surgical healing) to 21 
patients with "classic" osteosarcoma.6^ Of thirteen patients treated 
with amputation and no protocol deviation, twelve were completely free 
of disease at periods from one to 31 months after operation. An update 
of these data reported two subsequent relapses, such that 10 of the 13 
patients remained disease-free at a median of 19 months post-operatively, 
40 
and 3 to 34 months after the discontinuance of chemotherapy. Although 
admittedly these data may only signify an inhibition of tumor growth 
and a delay in the appearance of metastases, another report supports the 
probability that adjuvant chemotherapy is actually preventing the occurrence 
305 
of metastatic disease. At least two other recent prospective, 
controlled studies including adriam.ycin in a multiple drug adjuvancy 
340 305 protocol have substantiated this assessment. * 
Etiology and the Role of Tumor Immunity: 
Although there have been several theories of causation for osteo- 
sarcoma, including antecedent trauma and genetic origins^ , there 
•k 
is abundance evidence to suggest a viral etiology. Before reviewing 
the evidence, it is pertinent to first briefly review the requirements 
for proof of causality and to site the limitations imposed by these 
requi rements. 
As originally posed by Koch in 1891, there are three essential 
conditions which must be fulfilled in order to establish a causal rela¬ 
tionship between a suspected infectious agent and a particular disease. 
* REFERENCES: 1 -3,22,23,27,28,54-56,92-94,107-109,1 11 ,125,128,135,137, 
138,167,1 72,219,225 ,226 ,254,263-265 ,271 ,273,332,333 
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In general terms these are as follows: (1) the micro-organism must be 
observed in all cases of the disease in question; (2) it must be isolated 
and grown in pure culture, and (3) the micro-organism so isolated should 
reproduce the disease in other susceptible animals. Today a fourth 
criterion is generally recognized -- the demonstration in the infected 
host of circulating humoral and/or cellular immunity specific for the 
organism in abnormally high concentration, or an abnormally high spe- 
330 
cific imnunity to the infecting agent in a recently recovered host. 
Therefore, supporting evidence that viruses cause several human 
270 
cancers has been gathered in several ways. One approach has been to 
search for virus particles, viral precursors, and vi rus-speci fi c nucleic 
acids in human tumor biopsy samples and cultured tumor cells. A second 
method is to experimental ly induce tumors by inoculation of human tumor 
material or putative human oncogenic viruses. Resulting animal tumors 
are then examined for candidate human viruses. 
Data suggesting a viral etiology for human cancer have also accu¬ 
mulated by monitoring the ability of a virus to transform cells in 
culture. These transformed cells grow indefinitely in tissue culture, 
lose qualities of contract inhibition, alter their surface properties, 
and are often capable of inducing tumors. 
Finally, immunologic methods have been used to determine the pre¬ 
sence of tumor specific antigens and anti-virus antibodies in indivi¬ 
duals with cancer, their families and associates, and in large populations 
of people. Immunology has been a particularly powerful tool in estab¬ 
lishing a viral etiology for human malignancy, in that tumors induced 
m . ■ n 
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by the same oncogenic virus, even in unrelated animals or when producing 
histologically different malignancies, share at least one common tumor- 
specific anti gen. ^ As previously noted, this is in striking contrast 
171 237 
to tumors induced by the same chemical carcinogen. ’ 
In summary, then, while there is substantial evidence for a viral 
causation of some human malignancies, much of this evidence is indirect, 
depending on the host's recognition of, and response to, virus or vi rally 
determined antigens. Merely the presence of virus does not establish 
its causal role and yet direct proof -- to induce cancer by injection 
of the virus into healthy human subjects -- is morally and ethically 
prohibited. Nevertheless, even in bacterial non-tumor systems, the 
causal role of a particular micro-organism is sometimes justifiably 
adduced without complete fulfillment of all Koch's postulates, when the 
overwhelming preponderance of evidence presents a very high degree of 
...... 330 probability. 
Two groups of viruses have been consistently associated with natu¬ 
rally occurring cancer: oncornavi ruses containing single-stranded RNA, 
and herpesvi ruses composed of double-stranded DMA. Herpesvi ruses have 
been strongly linked to the causation of Burkitt's lymphoma, nasopharyn- 
geal carcinoma, and cervical carcinoma. Oncornavi ruses, especially 
C- and B- types, possess reverse transcriptase, which enables DNA to be 
produced on an RNA template, reversing the usual direction of informa¬ 
tion. This DNA intermediate is then integrated into the host genome, 
297 
causing neoplastic transformation by as yet unknown mechanisms. 
B-type particles and reverse transcriptase have been associated with 
218 human breast cancer , and several components of C-type viruses as 
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well as reverse transcriptase have been isolated from patients with 
1 24 
acute leukemia. It is predominantly this latter group of oncorna¬ 
viruses which have likewise been associated with human osteosarcoma, 
the evidence for which follows. 
Electron microscopic examination of thin sections of human osteo¬ 
sarcomata1 00,109 , their derived tissue culture cells106,226 anc| ce-j-| 
culture supernatants107,109,26^ have revealed C-type RNA particles. 
1 35 The incidence of these findings has varied; e.g., Gyorkey et al. 
found nine of 12 tumor biopsies positive for the virus, whereas Morton 
226 
et al. could not visualize any in the specimens from six sarcoma 
patients, yet visualized them in tissue cultures of the same tumors. 
The particles were similar to the tumor viruses first described by 
24 Bernhard , with an outside diameter of 85-90 millimicrons, appearing 
singly throughout the cytoplasm or in groups within cytoplasmic vesi¬ 
cles, and occasionally seen in the dumbbell shape of many murine leu- 
2 26 kemia and sarcoma viruses. 
Cell-free extracts of human osteosarcomata, many containing C-type 
viral particles, when inoculated into hamsters , guinea 
pigs26*1, and mice107 have reproducibl.y produced osteogenic sarcomata 
in these animals. Tissue sections of these animal tumors have then been 
108 
shown to contain C-type viral particles. 
Conversely, several studies have shown that murine sarcoma virus, 
strain Moloney (MSV), is capable of successfully transforming and repli- 
to 9 9 99 9 Q 17? 
eating in human diploid cell lines in culture. * ’ ’ ’ Similar 
results have also been obtained with feline leukemia and sarcoma vi¬ 
ruses.111,107 The results with MSV include the early and easily 
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reproducible transformation of some human embryo cell strains, and the 
interesting finding of a shift of viral tropism, once viral transforma¬ 
tion of the human cells has occurred. Thus, relative to its trans¬ 
forming function, the original double tropism (murine-human) of the virus 
shifted to an exclusively human one, retaining its transforming effect on 
22 fresh human cell cultures with excellent reproduci bi 1 i ty. 
Additional evidence for the etiology of an infectious agent is the 
133 254 273 
remarkable familial incidence of osteosarcoma. ’ * While ori¬ 
ginally this suggested to investigators the possibility of a genetic 
254 273 
origin for osteosarcoma 5 , as early as 1935 the question of an 
273 
adjuvant role of an infectious agent was considered. As many as 
138 four offspring in the same family have been afflicted. 
Finally, consistent with the intimate association of viral ly- 
induced tumors and immunological methods, there is abundant evidence 
to suggest the presence of a sarcoma specific antigen(s), the probabil¬ 
ity that this antigen is virus-related, and that host responses to this 
antigen may play a significant role in the in vivo destruction of 
tumors. 
A variety of immunological techniques have revealed the presence 
of at least one antigen which is specific for sarcomas. This antigen 
27 55 333 has been detected on the cell surface ’ ’ and in the cyto- 
plasm^’^’^’^’^3 of malignant cells, and host response has been 
, ,, , 54-56,125 . , , 27,92-94,219,225,226 ,263,265 ,271 ,332 both cellular and humoral. ’ *’**’*’ 
Using indirect immunofluoroescence (IF), common anti-sarcoma antibodies 
have been found in the sera of essentially all sarcoma patients against 
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o "7 o o r o n r 
autochthonous or allogeneic tumor lines. 7 in addition, approx¬ 
imately 85% of close family members and 90% of close, unrelated associ- 
q o nor 00£ 
ates have anti-sarcoma antibodies as determined by IF. ’ ’ Sera 
from unrelated normal blood bank donors have a variable incidence of 
positivity, generally reported as being between zero and twenty-nine 
per cent. Antibodies cytotoxic to human sarcoma cells 
332 have also been reported in patients with sarcomas. That the above 
anti-sarcoma antibodies are specific for sarcoma cells (of various 
histological types) has been convincingly demonstrated -- the sera are 
219 
non-reactive against a wide variety of other human cell lines. 
Cellular immunity in sarcoma patients is likewise sarcom-speci- 
54-56 1 25 55 fie. 5 In one study reported by Cohen et al. , peripheral 
blood lymphocytes from 14 of 18 patients with several histological 
types of sarcomata were cytotoxic to an allogeneic osteosarcoma cell 
line, but not to fibroblasts from the same patient. Lymphocytes from 
melanoma patients were consistently non-reactive. 
In keeping with the common antigenicity of vi ral ly-induced tumors, 
these immunologic data are perhaps sufficient in themselves to impli¬ 
cate a virus in the etiology of human osteosarcoma. To summarize these 
results, it may be instructive to briefly review one elegant study 
reported by Moore and Hughes. In this study, 42 sera from 31 sar¬ 
coma patients, 17 sera from 11 patients with various carcinomata, and 
34 sera from 18 non-tumor bearing control patients were tested by IF 
against 38 tissue culture lines, including those derived from sarcomas (16), 
carcinomas (7) and other tumors (2), embryonic tissue (8) and normal 
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adult tissues (5). In addition, IF tests were done to detect anti¬ 
nuclear antibodies (ANA) and smooth muscle antibodies (SMA), and sera 
were tested for HL-A antibodies by microcytotoxicity tests against a 
panel of 22 lymphocyte preparations. 
Their results, simply put, included the following: (1) There was 
a significantly higher incidence of anti-sarcoma antibodies (ASA) in 
sera from sarcoma patients than in carcinoma sera or sera from controls; 
(2) sarcoma sera showed no^ reactivity against 21 of 22 other human cell 
lines, including all those of embryonic origin; (3) sarcoma sera had 
significantly lower incidence of ANA and HL-A reactivity; and (4) sar¬ 
coma sera had a slightly increased incidence of SMA's. 
These results dramatically illustrate the specificity of the sar¬ 
coma antigens and help elucidate their nature. Failure to demonstrate 
HL-A reactivity, in addition to the presence of authocthonous anti¬ 
tumor activity, in the sarcoma sera strongly suggests that the antigens 
are not intra-cellularly expressed HL-A antigens. The lack of reacti¬ 
vity against cell lines recently derived from human embryonic tissue also 
minimizes the possibility that these antigens are of a fetal type. In 
addition, the immunologic specificity of the reactions renders "anti¬ 
genic conversion" by exogenous virus or mycoplasma unlikely, and these 
conclusions were also supported by the authors' inability to isolate 
mycoplasma from the tissue cultures. Finally, although these may 
202 
represent tissue-specific antigens which may be detected in vitro , 
as there was a slightly increased incidence of SMA in the sarcoma sera, 
a more interesting and likely possibility is that the antigens repre¬ 
sent intracel 1 ular products specified by an endogenous virus. Although 
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no electron microscopic evaluation of the malignant cells was performed, 
these exacting immunologic data provide a convincing complement to the 
previously cited data supporting a viral etiology for osteosarcoma. 
That the host response to osteosarcoma in man is significant for 
tumor destruction in vivo has been suggested by a wide variety of 
in vivo and in vitro correlates between the clinical progression of 
tumor and the hosts' immunological state. At the outset, it is impor¬ 
tant to clarify that the specific cellular and/or humoral mechanisms 
important for the destruction in vi vo of osteosarcomata have not yet 
been completely defined, and that some of the data supporting these 
mechanisms are in conflict. 
Studies of cellular immunity in patients with osteosarcoma have 
reported varied results, some studies indicating lymphocyte competence 
on? ?c ? 
in all stages of disease ’ , while others have reported apparently 
47 322 just the opposite. ’ These apparent differences are somewhat cor¬ 
rected when disparate methodologies are compared and clinical stage is 
taken into consideration. For example, whereas studies by McMaster 
202 130 
et al. and Golub et al. both show normal in vitro PHA-responsi ve- 
ness of lymphocytes in sarcoma patients, the latter study revealed 
decreased conconavalin A responsiveness in lymphocytes from these same 
patients. Golub et al . conclude from these data and those on patients 
with many other types of malignancies that con A is both a more sensi¬ 
tive index of lymphocyte proliferation defects and a better in vitro 
correlate of in vivo immunologic state in cancer patients. Thus, 
added credence is given to other reports of decreased lymphocyte mitogen 
responsiveness in sarcoma patients. 
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Del ayed hypersensitivity reactions (DHR) to common microbial anti¬ 
gens and DNCB, in vivo tests of non-specific cellular immune competence, 
130 
especially "recognition" competence , are more easily interpreted. 
In general, while at least one study reported normal delayed hypersen- 
253 
sitivity reactions in sarcoma patients , all studies have shown sig- 
Q "I I on or o 
nificantly decreased DHR in patients with advanced disease. ’ ’ 
That this may be important prognosti cal ly was shown by Eilber and 
91 Morton , who correlated DHR with clinical state before and after ampu¬ 
tation. In their study, 93% of DNCB-negati ve patients were either 
inoperable or developed early post-operative recurrences, whereas 92% 
of DNCB-positive patients were free of disease at six months after 
surgery. 
In vitro studies of humoral immunity have shown similar results. 
Cytotoxic antibodies detected in vitro are assumed to be significant 
332 for in vivo tumor destruction. In addition, antibodies detected by 
IF in sera from sarcoma patients have been significantly depressed in 
219 patients with metastatic disease , and serum factors blocking cell- 
mediated immunity have been found in 83% of patients with progressi vely 
54 5fi 145 
enlarging sarcomas. ’ ’ 
Finally, perhaps the functionally most important evidence clari¬ 
fying the significance of host immunity in osteosarcoma has come from 
studies of immunotherapy. Essentially all the main forms of immuno¬ 
therapy have been attempted, with varying amounts of vigor and with 
varying degrees of success; including, non-specific stimulation with 
BCG, passive transfers of specifically immune antibody, lymphocytes and 
transfer factor, and active immunization with various forms of tumor 
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cell vaccines.88,190,197,296,329 Active immunization with BCG and 
autologous tumor cells has induced in vitro heightened immune responses 
against tumor associated antigens, with occasionally beneficial thera- 
224 peutic results. A recent clinical trial using irradiated fresh 
autochthonous tumor cells as a vaccine adjuvant to surgery reported 
four of five patients disease-free at 20-31 months post-operatively. 
Though of small sample size, this study has revealed significant pro¬ 
longation of disease-free intervals in these patients, and underscores 
the other evidence supporting the substantial importance of tumor- 
specific host mechanisms in osteosarcoma. 
E. Animal Models of Osteogenic Sarcoma 
Characteristics of an Ideal Animal Model: 
An ideal laboratory model for osteosarcoma, in keeping with the 
character!'stics of the human tumor described in the previous discussion 
should include the following: (1) the tumor should arise "spontan¬ 
eously", or be induced reproducibly by a virus; (2) it should initially 
be well localized for surgical ablation and/or local therapeutic mani¬ 
pulation; (3) its pathological nature should include osteoid-producing 
malignant cells; and (4) it should have a clinical course similar to 
the human disease, with a similar incidence and distribution of meta¬ 
static disease. A final consideration is that reproducible assays 
must be -available for this model to permit evaluation of the immune 
response evoked by the tumor. 
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Historically, animal models of osteosarcoma have included spon¬ 
taneously arising tumors'^, tumors induced by external irradiation^ 
220 
or injection of radioactive isotopes , and tumors caused by chemical 
53 156 
carcinogens ’ or oncogenic viruses. A great variety of animal 
species have been used. 
Spontaneously arising osteosarcomas have been observed in dogs, 
3G but only very infrequently. Radiation-induced sarcomata, while very 
reproducible, produce only weak tumor-specific antigens, are poorly 
160 220 localized, and require long latency periods. ’ Chemical carcino¬ 
gen-induced tumors have greatly enhanced knowledge of tumor immunology 
in animals, but most importantly lack the common antigenicity seen in 
virally-induced tumors, as noted previously, and therefore lack a 
fundamental characteristic of human osteosarcomas. 
Models for osteosarcoma have included tumors induced by both DNA 
75 76 (SV-40) ’ 0 and RNA viruses in mice, hamsters and rats. Viruses have 
75,76 
, intra-muscu- 
, 102,141,199,217,286 . . .. ,121 ,295 . . . .... , lar * , intraperitoneal and intra-tibial 
produced tumors when inoculated by intravenous 
 
117,160 
routes. 
MSV - Mouse Systems: 
By far the most extensively studied animal models are the Moloney 
Sarcoma Virus (MSV)-induced tumors in mice. MSV is a known oncogenic 
RNA virus closely real ted to the murine leukemia virus (MLV) and 
sharing antigens with other closely related viruses of Friend and 
52,101,150 Rauscher. The induced tumors are highly antigenic, although 
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there are different neoplastic and immunologic responses to the inocu¬ 
lated virus both between different strains of mice ^ and ratsJ^ 
Thus, young BALB/c, C3H and (NZW x NZB) F -j (B/W) strains of mice all 
develop rapdily enlarging soft-tissue tumors, and while tumors regress 
in C3H mice, they grow progressively in BALB/c and B/W strains, and 
1 26 
each strain shows unique immunologic responses. The induced lesions 
also have been shown to vary substantially by different routes and 
doses of virus administration.^ 
The most thoroughly evaluated MSV model is the sarcoma induced by 
intramuscular inoculation of MSV into BALB/c mice. In this system, 
mice injected with MSV by three to four weeks from birth invariably 
develop tumors within approximately 10 days, which usually grow pro- 
102 141 199 21 7 gressively and kill the animals. ’ ’ ’ Older mice injected 
with MSV likewise develop tumors, but these usually reach a maximum size 
102 
of 10-15 mm and then regress. Immunosuppression of adult mice by 
X-irradiation^, ALS ^ or cortisone treatment^, or chemotherapy 
101 45 
with cyclophosphamide or daunomycin , causes a significantly de¬ 
creased incidence of tumor regression. 
Pathologic evaluation reveals these tumors to be rhabdomyosar- 
217 247 
comas. ’ The sarcomas contain and release virus as demonstrated 
121 by electron microscopy , the ability of cell-free tumor extracts to 
247 139 induce tumors in vivo , and focus formation in vitro. 
Immunologic studies in this system have been extensive, and will 
be discussed in greater detail later. Suffice it to say that a variety 
of immunological techniques have been used to demonstrate the presence 
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of anti-viral antibody, as well as both tumor-specific cellular and 
humoral immunity in vitro throughout the course of these tumors. Both 
in vi vo and in vi tro studies, therefore, have clearly demonstrated 
the significance of tumor immunity in the murine model for osteogenic 
sarcoma. 
Relative to the ideal animal model criterial proposed above, 
however, the MSV-BALB/c tumor system lacks two essential components: 
(1) the BALB/c tumors, consistent with other MSV-induced tumors in 
169 
mice , are myosarcomas, lacking any ability to produce osteoid; and 
(2) the incidence of metastases in this system is low, and metastases 
are not distributed in a pattern similar to the human disease. In 
addition, the small size of the animals makes effective surgical inter¬ 
vention difficult, and many animals often need to be sacrificed for 
sufficient serum and/or lymphocyte collection for in vitro immunological 
studies. 
MSV - Rat Systems: 
Factors such as these have led a few investigators to pursue an 
mcw • j a 4. , r . 51,121 ,160,169,295,320 r ^-i. MSV-mduced rat model for osteosarcoma. * ’ * Conflic- 
320 
ting reports exist as to the oncogenicity of MSV in rats; Ting states 
that MSV rarely produces tumors in intact newborn rats, and Kano-Tanaka 
169 
et a!. report that tumor induction in rats requires doses of the 
virus ten thousandfold higher than those in mice. These studies reveal 
the importance of the route of virus administration, as Ting used intra- 
peritoneal and Kana-Tanaka et al . used either intraperitoneal or sub- 
160 
cutaneous-intramuscular virus inoculation. Ikemoto and Yamamoto 
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however, report an 87.5% incidence of tumors when MSV is injected 
directly into the marrow of the tibia of newborn Wistar-Lewis rats. 
One uniform finding among these studies and those of Chesterman 
51 295 1 21 
et al. , Soehner et al . and Fuginaga et al. , is that rat sar¬ 
comas induced by Moloney Sarcoma Virus, regardless of route of inocu¬ 
lation, are almost invariably osteogenic in nature. This is in marked 
169 217 247 
contrast to the myosarcomas induced by MSV in mice. 5 ’ Con¬ 
sistent with mouse models though, was the preliminary evidence that 
suggested significant tumor immunity in these rat models for osteogenic 
sarcoma. This evidence included the increased incidence of sarcomas 
320 in thymectomized rats , and the total inability of investigators to 
induce tumors in the mature animals.^ 
Of the rat models for osteosarcoma, that described by Ikemoto and 
Yamamoto seemed to be the most promising, and it motivated Friedlaender 
and Mitchell at Yale to pursue this system further.^7 The results of 
their work will be described briefly. Following intra-tibial inocula¬ 
tion of MSV within 24 hours of birth, 97.7% of the animals developed 
localized tumors defined histologically as osteogenic sarcomas. Of 
those rats which could be evaluated, 77.9% had progressively enlarging 
masses and 22.1% had regressing tumors at the time of sacrifice or 
shortly after death. Although a detailed incidence study of metastases 
was not done, metastases were frequent in progressor animals, and these 
were most commonly to lungs. 
Tumor-specific cel 1-mediated cytotoxicity (CMC) was evaluated 
and found to be present in all animal groups tested from 19 to 88 days 
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of age. Since a single homogeneous tumor cell pool was not used through¬ 
out the experiments, however, changes in CMC did not necessarily reflect 
the changes of in vivo CMI during the course of the disease. Serum 
factors modifying this cell-mediated immunity (either "blocking" or 
"helping" factors) were also seen, and these were roughly correlated to 
the animals' clinical status. 
Thus, an animal model has been found which very adequately ful¬ 
fills the criteria previously proposed for correlation with human 
osteosarcoma. Intra-tibial inoculation of a virus has reproducibly 
produced well localized osteoid-producing tumors in newborn rats, and 
these tumors very readily metastasize in a pattern apparently similar 
to the human disease. While these data are preliminary, they suggest 
that further study of this model may help untangle the complex questions 
posed by osteosarcoma, including its relentlessly progressive nature 
and its alteration by immunological factors. 
F. Summary Statement of the Goals of the Present Investigation 
Osteosarcoma is a devastating and therapeutical ly resistant malig¬ 
nancy of young people, progressing to pulmonary metastases and death 
in 80% of patients within two years of its diagnosis. Abundant evidence 
supports a viral etiology for this tumor, including a common antigeni¬ 
city for several histological types of sarcomas. Tumor-specific 
immune mechanisms may play a significant role in preventing the usually 
rapidly progressive course of osteosarcoma. 
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Evidence has been reviewed that suggests that immunosuppression by 
chemotherapeutic agents may be counterproductive and clinically signi¬ 
ficant in cancer therapy. Thus, anti cancer agents are seen to be both 
tumoricidal and potentially immunosuppressive. Adriamycin is a rela¬ 
tively new anti cancer drug with a broad spectrum of tumoricidal activi¬ 
ties, but there is a paucity of data relative to its effects on tumor- 
specific immune mechanisms. Its tumoricidal action against osteosar¬ 
coma has been particularly striking, as it has postponed (and possibly 
prevented) the onset of metastatic pulmonary disease, and probably 
increased survival times. 
An initial investigation has suggested that an MSV-induced rat 
osteosarcoma may be an ideal model of the human disease. Initially 
localized, the primary osteoid-producing tumor metastasizes and is 
rapidly fatal to most infected animals. Assays have been used which 
document the presence of tumor-specific cellular and humoral responses 
in tumor-bearing hosts. 
With these considerations in mind, the present investigation was 
designed to fulfill three general goals: (1) To substantiate the 
extent of similarity of the rat osteosarcoma model to osteosarcoma in 
man, by evaluating its course, histology, and further documenting its 
incidence and distribution of metastatic disease; (2) to study the immu¬ 
nobiology of this tumor, with an emphasis on tumor-specific cellular 
responses throughout the course of disease; and (3) to evaluate the effects 
of adriamycin chemotherapy on the course and immune responses of tumor¬ 
bearing animals. 
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II. Materials and Methods 
A. Rats 
Pregnant Wistar-Lewis rats, an inbred strain, were obtained from 
Charles River Breeding Laboratories (Wilmington, Mass.) at 18 to 20 
days' gestation. Their litters, ranging from six to fifteen pups, were 
inoculated with virus within 24 hours of birth. Males and females 
were caged together until six weeks of age, and animals were weaned at 
20 days. 
B. Virus 
A Moloney strain of murine sarcoma virus (MSV-M), (hereafter re¬ 
ferred to as MSV) was obtained through the courtesy of Drs. J.B. Molo¬ 
ney and J. Gruber of the National Cancer Institute. This was propa¬ 
gated in BALB/c mice and harvested at 14 days by Mr. Richard Murahata 
215 
according to the method of Moloney. A virus suspension was prepared 
as 1 gram-equivalent/ml. and stored at -70°C until ready for use. 
After rapid thawing, the virus was iirmediately inoculated into the 
newborn rats. 
C. Infection of Rats 
Virus inoculation was performed according to the method originally 
described by Ikemoto and Yamamoto.After cleansing the left hind 
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1 imb of a newborn rat with alcohol, a 27 gauge needle was inserted into 
the marrow cavity of the tibia through the knee joint (Figure 2). A 
0.025 ml aliquot of the virus suspension in Eagle's Minimal Essential 
Medium (MEM, from GIBCO, Grand Island, New York) was then injected. 
Control animals received identical inoculations of MEM alone. 
Figure 2 
Technique of Virus Inoculation 
See text for explanation. 
D. Treatment 
Treatments were performed i.p. with adriamycin hydrochloride dis¬ 
solved in normal saline. Experimental groups were administered doses 
of 1 mg/kg/day or 2 mg/kg/day for three consecutive days. Control 
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animals were given comparable volumes of normal saline. Treatment was 
started at 10 days of age when approximately 90% of the animals in all 
groups had palpable tumors. 
E. Clinical Evaluation of Tumor Size 
Tumor growth and regression were evaluated by measuring with ver¬ 
nier calipers the greater of two transverse diameters of the left 
lower extremity. Uninfected control animals were also measured in order 
to discern the amount of increased diameter due to normal growth of 
these young animals. 
F. Pathology 
At the time of death or sacrifice for assays, the tumor site, re¬ 
gional lymph nodes, lungs, liver and spleen were grossly inspected. 
Portions of these tissues were preserved in 10% formaldehyde. Hard 
tissue (tumor and bone) was subsequently subjected to decalcification 
in serial baths of 5% formic acid, and all tissues were then embedded 
in paraffin. Tissues were stained with hematoxylin and eosin and/or 
Masson's trichrome preparation. 
G. Radiology 
At various times prior to death or at sacrifice, radiographs to 
illustrate bony structures were taken of both normal and tumor-bearing 
animal s. 
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H. Evaluation of Cell-Mediated Immunity 
Target Cells: 
The primary target cells for assay of cell-mediated cytotoxicity 
were from a single homogeneous line of tumor cells derived from a Wistar- 
Lewis rat (MSV/WL) and kept in tissue culture through serial passage. 
Originally, a growing tumor was sterilely removed from a donor rat, 
minced with scissors in MEM, and filtered through several layers of 
fine-mesh gauze. After centrifugation of the filtrate at 900 rpm for 
10 minutes, the cells were washed twice in MEM and resuspended in a 
Waymouth's medium (GIBCO) solution including 30% fetal calf serum (FCS), 
1% each L-glutamine, penicillin and streptomycin, .15% mystatin, and 
buffered to a pH of 7.4 with NaHCO^. After successful adherence and 
propagation of these original cells, the medium was changed in serial 
passages to an RPMI-1640 (GIBCO) solution containing 10% FCS, 1% each of 
penicillin and streptomycin, .10% mystatin and 1% tylocine, the latter 
to inhibit growth of mycoplasma organisms. 
In addition to the MSV/WL cells, normal fibroblasts from Wistar- 
Lewis rats were obtained from explants of rat skin of uninfected 
animals as described above for the tumor cells, and grown in tissue 
culture. Tumor cells from a mouse leukemia P383D1 were also used as 
target cells for two experiments, and these were obtained originally 
173 from Mr. Richard Murahata who had maintained them in tissue culture. 
All cells in culture were maintained in 30-ml Falcon plastic tis¬ 
sue culture flasks (Falcon Industries, Oxnard, Calif.). Tissue cultures 
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were maintained in a 37°C 5% CO^ atmosphere, and media were changed 
twice weekly and as necessary. 
At the time of assay or serial tissue culture passage, cells were 
harvested by subjecting them for 10 minutes to 2.5% trypsin diluted 
1:10 with a solution of phosphate buffered sal ine-ehtylenedi amenetet- 
raacetic acid (PBS-EDTA). After the majority of cells were floating 
free in solution, FCS was added in a volume equivalent to 30% of the 
total volume. The suspension was centrifuged at 1000 rpm for 10 minutes, 
and then either resuspended in medium for tissue culture, or counted, 
viability determined, and prepared for assay. Viability was determined 
31 by the trypan blue dye exclusion technique , and was consistently 
found to exceed 95%. 
Serum: 
At the time of assay, blood was obtained in one of two ways: when 
the animals were young (generally less than 35 days), groups of three 
animals were exsanguinated by jugular vein incision and their blood 
pooled, whereas older animals often supplied sufficient quantities 
through scalpel nicks made in the lateral tail veins. The blood was 
obtained after cleaning animal surfaces with alcohol, and following 
heat inactivation of the serum complement in a 56°C water bath for 
thirty minutes, the pooled serum was centrifuged at 2000 rpm for 20 
minutes. Finally, prior to assay, sera from both tumor-bearing and 
control animals were further purified by filtration through 45y minipore 
f i 1 te rs. 

-66- 
Lymphocytes: 
Peripheral blood was used as the source of effector cells, and 
lymphocytes were isolated by centrifugation of diluted blood over a 
33 Fi col 1-Hypaque density gradient. Staining of the effector population 
with Wright's stain showed it consistently to be composed of 90-93% 
lymphocytes, 2-5% polymorphonuclear leukocytes, 3-6% monocytes, and a 
variable small number of red blood cells. When red blood cell contami¬ 
nation occasionally approached 5%, these cells were removed by treatment 
30 
with a tns buffered-ammoni urn chloride solution. Trypan blue exclu¬ 
sion tests on the effector population prior to assay invariably showed 
greater than 95% viability. 
Visual Microcytotoxicity Assay: 
309 A modification of the micro-assay of Takasugi and Klein was used. 
Assays were always performed the same day as lymphocyte and serum iso¬ 
lation, and were carried out in Linbro tissue culture trays (Linbro 
Industries, New Haven, Conn.) with wells 16 mm in diameter. 
Twenty-four hours prior to assay, each well was seeded with 200 
viable target cells suspended in 0.5% of the RPMI-1640 solution pre¬ 
viously described, and incubated at 37°C in a 5% CO^ atmosphere. Immed¬ 
iately prior to assay, the solution over the adherent cells was pipetted 
off. 
One-tenth milliliter of either normal or immune heat-inactivated 
and purified serum in a 1:5 solution with MEM (containing 20% FCS and 
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antibiotics) was then added to each well. The tissue culture tray was 
then incubated for one hour at 37°C. 
Following incubation, 40,000 purified effector cells from tumor¬ 
bearing or control animals were added to each well in .5 ml of a solu¬ 
tion of MEM as above. The resulting effector: target cell ratio was 
therefore approximately 200:1. The volume of serum in each well was 
then raised to .5 ml, and the trays subsequently incubated in a 37°C, 
57o CO2 atmosphere for an additional 48 hours. After removal of the 
solutions in each well and washing the wells once with cold MEM, the 
remaining cells were stained with Wright's stain and visually counted 
using a Nikon MS inverted phase-contrast microscope. 
Each assay included wells with different combinations of compo¬ 
nents, including: 
A. target cells, immune lymphocytes, immune serum 
B. target cells, inmune lymphocytes, normal serum 
C. target cells, normal lymphocytes, normal serum 
D. target cells, medium alone 
E. target cells, normal lymphocytes, immune serum 
Virtually all assays included wells A-D above, and many assays included 
the fifth well. "Target cells" most often were MSV/WL, but tests 
using normal fibroblasts and P388D1 cells were also performed. 
Tests were always done in triplicate and reported as the mean + SE. 
Results were expressed as percent specific lysis, or: 
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100 x 1 - 
' tumor cells remaining in experimental well n 
.tumor cells remaining in well with normal lymphocyte/- 
Comparison of wells B and C measured cel 1 -mediated immunity (CMI), 
while comparison of wells A and C indicated serum modification of CMI 
("blocking" or "helping" factors). Well E tested for antibody-depen- 
dent lymphocyte-medi ated cytotoxicity, while well D controlled for the 
presence of non-specific cytotoxicity in normal animals. Specificity 
of humoral and cellular immunity was tested by considering lysis of 
normal fibroblasts and the xenogeneic tumor line as compared to MSV/WL. 
Microtoxicity Assay with Isotopic Labelling: 
Several types of assays designed to measure CMI using the percent 
release by killed target cells of a radioactively-1abelled substance 
were attempted. The assay employed which most closely correlated with 
results from the visual assay is described in the following paragraphs. 
Seeding of target cells and the addition of lymphocytes and serum 
were accomplished in a manner identical to the visual assay. In this 
method, however, 1000 target cells were originally seeded, while the 
effector:target cell ratio was maintained at 200:1. 
At the end of 48 hours' incubation, the wells were viewed under 
the phase-contrast microscope for the presence of lymphocytes, and 
subsequently flushed vigorously with a suction bulb 15 times to remove 
1 oosely-adherent effector cells. All wells were then washed and flushed 
three times with ice-cold MEM and the tray inverted and shaken to remove 
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effector cells which might incorporate the radiolabelled substance. 
After the last washing, wells were again viewed under the phase-contrast 
microscope, and it was consistently observed that only 1-2% of the 
effectors remained in the tray. 
3 
One milliliter of 1 yCi/ml H-thymidine (New England Nuclear, 
Boston, Mass.) in MEM solution with 10% FCS, specific activity 50.7 mM, 
was added to each well. The tissue culture tray was then incubated in 
a 37°C, 5% C02 atmosphere for an additional 5 hours. 
After incubation, wells were washed twice with ice-cold MEM as 
before, and the adherent cells removed by exposure to a 0.25% trypsin 
solution as above. Cell solutions were transferred to Falcon 2057 
tubes (Falcon Industries, Oxnard, Calif.) containing 0.3 ml FCS, cen¬ 
trifuged at 1000 rpm for 10 minutes, and the resultant supernatant fluids 
discarded. Eight-tenths milliliter of a solution containing normal 
saline and human serum and 1.0 ml of 10% trichioroacetic acid (TCA) 
were then added to the tubes. Tubes were then vortexed and refriger¬ 
ated overnight. 
The next day, tubes were centrifuged at 1700 rpm for 10 minutes. 
The supernatants discarded, and to each tube was added .4 ml 100% formic 
acid and 3 ml absolute alcohol. The resultant solution was vortexed, 
poured into scintillation vials containing 10 ml of a scintillation 
fluid (PP0-P0P0P, Mallinckrodt Chemical Works, St. Louis, Mo.), and 
counted for one minute at 4°C in a Packard scintillation counter. 
Tests, as before, were always done in triplicate. Results were 
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re ported as cpm + SE, and the per cent lysis was calculated as: 
cpm in test well 
cpm in control well 
I. Evaluation of Humoral Immunity 
Serum: 
Serum for evaluation of humoral immunity was obtained at the time 
of assay for CM I. Undiluted serum was gathered following clotting of 
whole blood, and the constituent complement heat-inactivated at 56°C 
for thirty minutes. Sera were then frozen at -70°C until the time of 
assay, when they were quickly thawed for use. 
Target Cells: 
Target cells for the cytotoxic antibody assay were LSTRA tumor 
cells, a line anti geni cal ly cross-reactive with MSV-derived cells and 
245 
used by others as targets for MSV-specific humoral immunity. These 
cells were propagated in BALB/c mice. 
LSTRA cells were collected by exposure of the mouse peritoneum 
and lavage and suction with a solution of Fischer's medium (GIBCO) and 
10% FCS. The cells were subsequently counted and their viability de¬ 
termined by trypan blue exclusion. As before, where red blood cell 
contamination was a problem, these were removed by treatment with 
tris-buffered ammonium chloride. 
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Cytotoxi c Antibody Assay: 
168 A slight modification of the micromethod of Kaliss was used to 
51 
assay antibody-induced cytolysis by the release of Cr. Two tenths mil 
51 liter of 1 mCi/ml Cr, specific activity 51.9 mM, were added for 
every 5x10 viable LSTRA target cells, and the resultant solution incu¬ 
bated in a 37°C shaking water bath for 5 hours. After incubation the 
cells were washed with ice-cold Fischer's medium containing 10% FCS, 
centrifuged at 1000 rpm for 10 minutes, and these procedures repeated 
for three additional washings. After viability was determined and the 
g 
cells were counted, the cell concentration was adjusted to 10 cells/ml 
solution. 
The assay, briefly summarized, was as follows: reagents dispensed 
sequentially into 0.3 ml wells of Linbro plastic trays (Linbro Chemical 
Co., New Haven, Conn.) included 0.05 ml each of Fischer's medium with 
10% FCS, antisera which were serially titrated, radiolabelled LSTRA 
cells, and 1:3 dilutions of guinea pig complement. As titrations were 
carried out through eight wells with 0.05 ml of solution being discarded 
from the last well, the final volume in all reaction mixtures was 0.15 ml 
Controls were wells which, in addition to targets, contained medium 
alone (cell control), only complement and medium (complement control), 
only 1 N HC1 and medium (indicating maximum lysis), and normal serum 
instead of antiserum (normal serum control). After 10 minutes' incu¬ 
bation at 37°C, the trays were immediately sealed with pressure sensi¬ 
tive adhesive cellulose and incubated an additional 45 minutes. 
Immediately following incubation, the tray was chilled for 5 min. 
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on ice and centrifuged for 10 min. at 800 rpm. Subsequently, .05 ml 
of supernatant was carefully removed and measured for radioactive con¬ 
tent in a Picker gamma counter (Picker Nuclear, U.S.A.). Results were 
expressed as cpm, and a percentage of specific release was calculated. 
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III. Results 
A. Natural Course in Untreated Animals 
The MSV-inoculated extremity appeared grossly normal until the 
animals were six to ten days of age. By nine days post-inoculation, 
approximately 90% of the animals which would ultimately develop local¬ 
ized tumor masses had palpable swellings, and daily observation revealed 
that 96% of all infected animals became tumor-bearing. 
In successfully infected rats, tumors invariably grew progressively 
and killed the animals. Of 22 animals, nine were not sacrificed for 
immunological assays, and all of these were dead by 64 days of age. 
Most animals died within 10-12 days of clinical tumor detection, and 
this is reflected in a median survival time (MST) of 20.0 days. Survival 
data are depicted in Figure 3. 
Tumors in untreated animals enlarged progressi vely, and the ori- 
ginally well-1 ocal i zed hard tumor mass often extended from the tibia 
to involve both the femur and fibula (Figure 4). Animals surviving 
to 64 days thus had enormous tumor masses, and therefore no clinical 
"regressor" animals were seen in untreated animals. The change in tumor 
size over time is depicted in Figure 5. 
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Figure 3 
Survival of Treated versus Untreated 
MSV-inoculated Tumor-bearing Rats 
□- Untreated tumor-bearing animals 
O- Tumor-bearing animals treated with adriamycin, 1 mg/kg/day 
©- Tumor-bearing animals treated with adriamycin, /’mg/kg/day 
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Fig ure 4 
An untreated animal 15 days after inoculation of MSV into 
marrow of left tibia. Tumor at necropsy involved both 
left tibia and fibula. 
B. Activity of Adriamycin on Tumor Progression 
Survival: 
Preliminary experiments were attempted using adriamycin at doses 
of 3 mg/kg/day and 4 mg/kg/day administered i.p. for three days 
beginning on day 10. These animals became sickly, failed to gain weight 
like the tumor-bearing control animals, and died within two weeks of 
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starting treatment. That these animals succumbed to drug-associated 
infection was supported by the lack of evidence for accelerated tumor 
growth and the findings of pulmonary congestion and viscous intra-peri- 
toneal exudates at necropsy. 
Of the animals treated with adriam.ycin at 1 mg/kg/day or 2 mg/kg/ 
day administered i.p. on the same schedule as above, 93% had developed 
palpable tumor masses by two weeks of age. The incidence of tumor¬ 
bearing animals was similar in both of these experimental groups. 
Ten successfully infected rats treated with the lower dose of ad- 
riamycin were not sacrificed for immunological assays and therefore 
are included in survival data. In contrast to the untreated animals, 
deaths in this group were distributed over several weeks. While the 
first animal died at 20 days post-infection, five rats survived more 
than 95 days. Median survival time in this group was greater than 91 
days. 
In the group treated with 2 mg/kg/day adriamycin a similar sur¬ 
vival distribution was noted. Eight tumor-bearing animals survived 
from 28 to more than 95 days post-infection, with a small cluster of 
animals dying between 60 and 79 days. Median survival in this group 
was 63.5 days. 
The composite MST for the adriamycin-treated rats was 77.5 days. 
When compared to the MST of 20.0 days in untreated animals, this differ¬ 
ence is significant at the p < .05 level as evaluated by the "t" test 
for medians. 
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Figure 5 
Change in Average Left Lower Extremity 
Diameter During the Course of Disease in 
Treated versus Untreated Tumor-bearing Rats 
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tween untreated 
and treated ani¬ 
mals significant, 
p <. 001 
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- maximum transverse plane diameters, left lower extremity; cor¬ 
rected for minor differences in original diameters 
- when few animals were surviving in the untreated group, death of 
one animal with a large tumor, as on day 34, spuriously lowered 
average tumor diameters, which then returned (day 45) to high levels 
- uninfected normal Wistar-Lewis rats - growth due to age changes 
- untreated tumor-bearing animals 
- tumor-bearing animals treated with adriamycin, 1 mg/kg/day 
- tumor-bearing animals treated with adriamycin, 2 mg/kg/day 
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Tumor Growth and Regression: 
In contrast to control animals, rats treated with adriam.ycin at 
either dose developed tumors that grew slowly but progressively for 15 
to 20 days post-infection, and then either progressed very slowly, 
stabilized, or regressed. Treated animals that succumbed to their 
tumors had masses that were measurably smaller than those of untreated 
rats. 
Average tumor diameters over time were compared between treated 
and control animals (Figure 5). At all points beyond 25 days, tumor 
diameters in treated rats were significantly smaller, as evaluated by 
the Student's t test (p < .001), than those of untreated animals. 
Animal tumor status was classified as either "progressor" or "re¬ 
gressor". Regressor animals had tumors which were either diminishing 
in size at the time of assay, or were microscopically absent at the 
time of sacrifice for histologic examination. 
Seven of 17 animals (41%) treated with 1 mg/kg/day adriamycin 
were classified as regressors. When compared to the 22 control animals 
by chi-square analysis, there were significantly more regressor animals 
in this treated group (p < .005). 
By comparison, 18% of 22 animals treated with the higher doses of 
adriamycin were classified as regressors. This incidence, too, was 
significantly different from controls (p < .05). Chi-square analysis 
confirmed that there were significantly more regressor animals in the 
combined experimental groups than in the untreated group (p < .001). 
/ 
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The effects of treatment on the natural course of the disease are 
summarized in Table I. 
TABLE I 
Course of Disease in Untreated and Adriamycin-treated Animals 
Group Tumor Growth 
Pattern 
Median 
Survival Time 
(days) 
Progressors 
(No.) 
Regressors 
(No.) 
Regressors 
(%) 
Untreated Rapidly 
Progressive 
20 22 0 0 
Adr. 1 mg/kg Slowly Pro¬ 
gressive, re¬ 
gression com¬ 
mon 
91 + 10 7 41 
Adr. 2 mg/kg Slowly Pro¬ 
gressive, oc¬ 
casional re¬ 
gression 
63.5 18 4 18 
C. Gross Pathology 
The primary tumor mass was either rubbery or hard to palpation and 
intimately associated with the long bones of the lower extremity. 
Animals surviving for longer periods generally had masses which extended 
proximally from the tibia to involve the femur and even invade the 
retroperitoneal space. In the latter cases, renal excretion was ob¬ 
viously impeded by ureteral obstruction by the tumor mass. The non- 
encapsulated portions of the tumors were whitish-gray and fleshy in 
appearance,and on sectioning were "gritty". 
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117 As performed by Friedlaender and Mitchell , control animals were 
inoculated intra-tibial ly at birth with 0.025 ml of MEM in order to 
rule out the possibility that mechanical injury to the bone might stimu¬ 
late stem cells of the periosteum or endosteum to produce bone, and thus 
simulate a bone tumor. Again, there was no evidence on gross or histo¬ 
logic examination of control animals to suggest a significant altera¬ 
tion of normal bony architecture. 
Opening the peritoneal cavity revealed a variety of pathological 
changes in progressor animals. Visibly enlarged lymph nodes, some 
reaching 1.5 cm in diameter, were present in approximately 10% of 
animals. Inguinal lymph nodes were most frequently enlarged, although 
the largest glands were often the inferior mesenteric or para-aortic 
nodes. On gross examination their appearance was similar to the pri¬ 
mary tumor, being fleshy and rubbery or hard. 
Although varying in size, both liver and spleen were grossly normal 
in appearance. Livers were smooth and regular in consistency without 
visible nodularity. Some livers were large, and on sectioning revealed 
the typical "nutmeg" appearance associated with passive congestion. 
Spleens varied much more in size, and both small and large spleens 
were noted with both progressor and regressor animals. In the prelim¬ 
inary experiments with 3 mg/kg and 4 mg/kg adriamycin, necropsied 
animals invariably had very small spleens as compared to their untreated 
tumor-bearing controls. No such correlations between spleen size and 
treatment with the lower doses of adriamycin could be made. 
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In animals with very large tumors, obstruction of both the gastro¬ 
intestinal and genitourinary tracts was obvious on gross examination. 
Greatly dilated ureters and loops of bowel were seen, and in some cases 
the sections of bowel were clearly necrotic. 
On opening the thoracic cavity of progressor animals, a viscous 
bloody effusion was occasionally seen bilaterally, which on microscopic 
examination contained many large and pleomorphic tumor cells. 
The lungs of tumor-bearing animals revealed a spectrum of changes 
on gross examination. Virtually all lungs had small areas of consoli¬ 
dation which became more prominent when immersed in 10% formalin. At 
the other extreme, several animals had large, firm, whitish-gray, clearly 
circumscribed nodules scattered bilaterally throughout the pulmonary 
lobules. Approximately 30% of necropsied animals had these grossly 
apparent lung metastases. 
All four extremities were palpated daily for evidence of long bone 
metastases. Together with necropsy data, a clear pattern emerged 
revealing the predilection of treated animals for long bone metastases. 
Of 22 untreated animals, there were none with osteosarcoma metastatic 
to other long bones. In contrast, of 39 adriamycin-treated rats, four 
animals had a total of five palpable tumors in other long bones. Of 
these, one appeared in an animal with the lower dose of adri amyci n, and 
the remainder occurred in rats treated with adriamycin at 2 mg/kg/day. 
These occurred exclusively in the forearms of the treated animals, and 
on necropsy were found intimately associated with either the radius 
or ulna (Figure 6). All long bone metastases first appeared between 
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Figure 6(a-b) 
X-rays of Two Adriamycin-treated Tumor-bearing 
Rats with Long Bone Metastases 
(a) M day old animal treated with adriamycin, 1 mg/kg/day. Left lower 
extremity bears primary tumor, and right upper extremity shows destruc¬ 
tion by metastatic lesion, (b) 26 day old animal treated with adriamy¬ 
cin, 2 mg/kg/day. Both upper extremities have metastatic lesions in¬ 
volving both radius and ulna. 
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21 and 29 days post-infection. On gross inspection, they were large 
masses identical in appearance to the primary tumors. When compared by 
chi-square analysis, treated animals were shown to have significantly 
more long bone metastases than the untreated controls (p < .025). 
Animals treated with the higher dose of adriamycin had more of these 
metastases than animals treated with the lower dose, although this 
difference was not statistically significant (p > .05). 
Microscopic Pathology: 
Organs from 27 animals of all experimental groups were examined 
histologically using the hematoxylin and eosin (H and E) staining 
technique. Most often the primary tumor, lung, liver, spleen, lymph 
nodes and long bones with gross tumor involvement were evaluated. In 
treated animals, organs from both progressor and regressor animals 
were examined. Except to attempt evaluation of equivalent numbers of 
each treatment group, and to sample animals with different tumor status, 
sampling for histologic examination was made on a random basis. 
The primary tumor was characterized by variation from lesion to 
lesion and from area to area within the same lesion, typical of osteo- 
sarcoma in man as described by Jaffe (Figure 7). In nonossified 
areas, the tissue was either chondroblastic, or more commonly, fibro¬ 
blastic in nature. Cells in these areas were anaplastic, spindle- 
shaped, or round in appearance, the latter located in irregularly ar¬ 
ranged lacunae suggesting neoplastic cartilage formation. 
In more anaplastic areas, cells were sometimes multinucleated, 
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F'igure 7(a-g) 
Microscopic Appearance of Primary Tumors 
(a) Low power view of tumor-bearing extremity revealing normal growth 
plate (GP) and marrow CBM)- Normal bone (B) is being compressed by tu¬ 
mor bone (TB) and the marrow replaced by undifferentiated sarcomatous 
tissue (S). Highly anaplastic tissue (A) has caused periosteal eleva¬ 
tion (P). (b) Higher power view of segment of same bone as in 7(a). 
Neoplastic cartilage (C) is also apparent in this photomicrograph. 
(c) Widely scattered spindle-shaped cells remarkably similar in appear¬ 
ance to tumor cells in tissue culture (Figure 11). (35X) 

803 
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(d) Higher power view of endosteal bone compression by sarcomatous tissue 
From left to right in this section are: normal bone marrow, normal endos¬ 
teal bone, reactive and/or neoplastic bone, and undifferentiated sarcoma. 
Long axis of bone is vertical in this micrograph, periosteal elevation out 
of section at far right. (35X) (e) Highly anaplastic sarcomatous tissue 
with many rnultinucleated giant cells. (35X) 
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7f 
(f) Section revealing three major components of primary tumors, from left 
to right: neoplastic bone, neoplastic cartilage, and highly anaplastic 
sarcomatous tissue. (g) At left, neoplastic cartilage, with irregularly 
sized, shaped and arranged lacunae, and many mitotic figures. At right, 
poorly differentiated malignant bone. (35X) 
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or more often contained a single nucleus with from 1 to 3 large nucleoli 
Mitoses in these areas were common. 
Sections containing widely separated spindle-shaped cells generally 
juxtaposed areas in which the spindle cells were more densely aggregated 
with substantial amounts of intracellular fibrillar collagenous material 
The latter dense areas were usually seen in endosteal bone, and consti¬ 
tuted the predominant fibroblastic and undifferentiated osteosarcomatous 
tissue which characterized these tumors. 
The presence of neoplastic osteoid in the primary tumors defines 
them as osteosarcomata, and malignant bone in addition to undifferen¬ 
tiated sarcomatous tissue was likewise a prominent component of the 
tumors. True tumor bone, with osteoid trabeculae and calcium deposi- 
tion, was seen in its various stages throughout the tissue. While 
early neoplastic bone was confined to an endosteal location, bone in 
older animals with grossly larger tumors disrupted the cortex and was 
even seen invading normal muscle tissue. Some sections revealed an 
intermediate stage in which neoplastic bone, reactive bone, and perio¬ 
steal elevation were observed. 
Microscopic metastases were seen in the lungs of 89% of the 27 
animals in which their presence was evaluated. With equivalent numbers 
of each experimental group being examined, there were no differences 
in the frequencies of lung metastases between the groups. Micrometa- 
stases were seen in animals dying from tumor or sacrificed from 15 to 
64 days of age. 
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The pulmonary lesion was almost invariably a highly anaplastic, 
undifferentiated sarcoma, without any clear cartilage or bone-forming 
activity. Specimens were examined microscopically without knowledge 
of experimental group, and lesions were graded on a 0-4+ scale as to 
the presence and extent of neoplastic tissue. Metastases varied widely 
relative to numbers of neoplastic cells and amount of stroma. One-plus 
lesions contained neoplastic cells dispersed throughout the lung paren¬ 
chyma, and often at pleural surfaces, consistent with the hematogenous 
nature of their dissemination. Four-plus lesions additionally had 
dense, well -circumscribed areas of sarcomatous tissue which almost 
completelv obscured the normal lung architecture. Typical pulmonary 
lesions are depicted in Figure 8. 
There were several types of microscopic changes noted in the 26 
•k 
liver specimens of tumor-bearing rats. Some of these changes appeared 
to be merely the result of passive congestion of the livers without 
concomitant extensive necrosis and/or infiltration with tumor cells. 
These were organs which on gross sectioning showed the typical "nutmeg" 
liver appearance characteriStic of chronic passive congestion. The 
predominant cellular pathology in these specimens was a centri 1 obular 
fatty change of the hepatocytes. 
Other specimens showed more extensive fatty change with or with¬ 
out major hepatic morphologic changes and infiltrates. Where destruc¬ 
tion and architectural changes were predominant, cellular infiltrates 
* Evaluation of several liver sections was aided by the kind assistance 
of Dr. Joseph R. Bloomer, Department of Internal Medicine, and Dr. John 
A. Ogden, Department of Surgery, Yale University School of Medicine. 
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Figure 8(a-d) 
Microscopic Appearance of Lung Sections 
(a) Normal rat lung. Lacy alveolar walls and well aerated ducts and sacs. 
(b) One-plus metastatic pulmonary lesion. Alveolar walls are thickened by 
hematogenously disseminated pleomorphic tumor cells. Fibrinous and hemor¬ 
rhagic intra-alveolar congestion. The air spaces are largely well pre¬ 
served. (35X) 
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(c) Two to three-plus metastatic pulmonary lesion. Generalized alveolar 
wall thickening and dense aggregates of undifferentiated sarcomatous tis¬ 
sue are seen. Some preservation of air spaces, (d) Four-plus pulmonary 
metastasis. Dense sarcomatous tissue completely surrounds vessel in this 
section* and few open airways exist. Grossly, there were hard pulmonary 
nodules. This rat lived 64 days. (35X) 
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were common. Infiltrates included fibroblasts and more atypical, pleo¬ 
morphic cells embedded in connective tissue stroma. These cells closely 
resembled those seen in pulmonary metastases. The lesions were occa¬ 
sionally well circumscribed and dense, occurring in non-portal areas, 
but more commonly were less organized and seen diffusely throughout a 
generally disorganized hepatic parenchyma. 
Because infiltrates were suggestive, but not diagnostic of meta¬ 
stases, an attempt was made to differentiate morphologic changes secon¬ 
dary to inanition from those due to tumor infiltration. In addition 
to H and E staining, some liver sections were stained by the Masson 
trichrome technique, in the hope that reparative hepatic fibrosis could 
be distinguished from fibroblastic or undifferentiated sarcomatous 
infiltrates. In the sections so stained, color changes characteristic 
of hepatic reticulin were not seen in fibrotic areas. However, the 
cellular infiltrates and stroma were not entirely comparable to the 
metastatic patterns seen in lung, in which infiltrates were clearly 
malignant and similar to neoplastic changes observed in malignant bone. 
Thus, those hepatic sections with major structural changes and suggestive 
cellular infiltrates were classified as "suspicious" of containing 
metastatic disease, but not definitive. 
Of the 26 liver specimens examined microscopical ly, 12 were con¬ 
sidered suspicious for metastasis by the criteria defined above. The 
incidence of suspicious lesions did not vary significantly by experi¬ 
mental group; approximately 40-50% of both treated and untreated animals 
contained such hepatic infiltrates. Liver sections with probable meta¬ 
static infiltrates (containing "suspicious" lesions) are illustrated 
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Figure 9(a-d) 
Microscopic Appearance of Liver Sections 
(a) Normal liver. Central vein with radiating cords and sinusoids. 
(b) Typical "suspicious" hepatic lesion with diffuse destruction and pleo 
morphic cellular infiltrate. Few "normal" hepatocytes and little parenchy 
trial organization is preserved. (35X) 
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(c) Higher power view of lesion similar to that seen in 9(b). Diffuse 
hepatic parenchymal destruction and invasion by hyperchromatic, pleomor¬ 
phic cells is evident. (70X) (d) A second type of "suspicious" hepatic 
lesion. Hepatic architecture is generally preserved, with several foci 
of well-circumscribed pleomorphic infiltrates such as this one. (70X) 
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in Figure 9. 
Long bones which had grossly apparent metastatic disease showed 
typical osteosarcomatous changes on microscopic examination. As pre¬ 
viously noted, 10% of the adriamycin-treated animals had long bone 
metastases, as compared to 0% of the untreated control rats. 
Of 26 spleens examined microscopi cal ly, none showed convincing 
metastatic infiltrations. Many specimens revealed a general hyper- 
cellularity when compared to uninfected normal rat spleens, with 
especially prominent germinal centers. 
Lymph node specimens revealed tumor infiltrations similar to that 
seen in metastatic lung sections, with dense fibroblastic osteosarco¬ 
matous tissue distributed in well -circumscribed lesions. Since clini¬ 
cally small nodes were difficult to find and remove from tumor-bearing 
rats, a significant bias was placed on the samples obtained. Thus, 
only a fairly accurate 10% figure can be sited as the incidence of 
lymph node metastases, and this from gross inspection of the animals 
at necropsy. 
Table II summarizes the pathologic findings in the three experi¬ 
mental groups. 
E. Radiographic Appearance 
Radiographs taken at various intervals during the course of dis¬ 
ease reflected the microscopic pathology of the primary tumors. The 
\ 
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Table II 
Microscopic Pathology: Incidence and Distribution of 
Metastases 
Group Long Bones 
% 
Lung 
% 
Li ver* 
% 
Spleen Lymph 
Nodes %** 
Untreated 0 89 50 0 10 
Adr. 
1 mg/kg/day 6 88 38 0 10 
Adr. 
2 mg/kg/day 14 90 50 0 10 
* Figures reported in this table represent probable metastases, 
or "suspicious" lesions. See text for explanation. 
** Figures represent estimates derived from gross inspection of 
animals at necropsy. See text for explanation. 
normal contours of the involved long bones of the lower extremity were 
expanded and eventually destroyed, and the tumor mass was characteri zed 
by both osteoblastic and osteolytic areas (Figure 10). Long bone 
metastases showed similar radiographic changes (Figure 6). 
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Figure 10 
X-ray appearance of normal and primary tumor-bearing limbs. 
The normal limb contour was invariably expanded or destroyed, 
and lesions were radiographically blastic and/or lytic. 
F. Tumor Cells in Culture 
A single homogeneous line of MSV/WL tumor cells was kept in tissue 
culture through serial passage in RPMI medium supplemented with 10% 
FCS and antibiotics. At no time were fungi or typical mycoplasma 
intracellular inclusions seen under the inverted phase contrast micro¬ 
scope. 
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Tumor cells had a plating efficiency of approximately 50% and a 
doubling time of about. 24 hours.After adding 2x10^ cells to a 30 ml 
tissue culture flask and incubating them in a 37°C 5% CO^ atmosphere, 
cells became adherent by approximately 5 hours and confluent in three 
days, necessitating repeated cell passage. 
There were two predominant cell types observed in tissue culture 
(Figure 11). The first was characterized by a large, granular and 
often nuclei a ted nucleus with scant cytoplasm. The second cell type 
was spindle-shaped or stellate, with long cytoplasmic, processes often 
Figure 11 
Osteosarcoma cells from Wistar-Lewis rats in tissue culture, 
as viewed under the inverted phase-contrast microscope (547X). 
See test for explanation. 
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extending from one or more centrally located oval nuclei. Both cell 
types were adherent to plastic surfaces and appeared to replicate at 
equal rates. 
G. Cel 1-Mediated Immunity and its Serum Modification in vitro 
as Measured by a Visual Assay 
Cel 1-Mediated Immunity (CMI) in Untreated Animals through the Course 
of Disease: 
Cell-mediated immunity was tested in untreated animals by a 48 
hour visual microcytotoxicity assay at three to nine day intervals when 
animals were 10 to 48 days of age. Results are summarized in Table III 
and illustrated graphically in Figure 12. All assays included control 
wells containing lymphocytes and serum from uninfected (normal) animals, 
or medium alone, in addition to the MSV/WL target cells. The normal 
lymphocytes were virtually never cytotoxic for MSV/WL as compared to 
wells with medium alone, and were therefore considered the standard 
control wells against which specific lysis by iranune lymphocytes, 
CMI(L), or immune lymphocytes and anti-serum, CMI(S), were compared. 
All experimental wells were done in triplicate, and the significance 
of specific lysis was evaluated by the Student's t test. 
Specific lysis by lymphocytes from tumor-bearing animals was pre¬ 
sent in all animal groups tested between 14 and 48 days of age. Acti¬ 
vity was difficult to evaluate on day 10, at which time normal serum 
was nonspecifically cytotoxic to target cells, presumably due to factors 
in the serum of animals which had recently been suckling. CMI(L) was 
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TABLE III 
Activity of Immune Lymphocytes and Serum from 
Untreated Animals versus MSV/WL Cells 
Age 
(days) 
Cells in 
Control 
Wells* 
Cells in Experimental 
Wells CMI(L) 
•kkk 
% 
CMI(S) 
*** 
. % Lymphocytes 
Alone** 
With Immune 
Serum 
10 192+6 - 144±15 - 25 
14 511±16 505+24 409±17 1.2 20h 
21 222±19 98+15 81+11 56k 64 
28 437+47 341±24 159+24 22k 64h 
31 211±6 193±19 1 53±5 9 28h 
34 104±8 88±4 7 ±3 15k 93h 
39 109±14 57±4 45±6 48k 58h 
48 213±5 1 58±7 88±6 26k 59h 
*- All control wells contained lymphocytes and serum from uninfected 
rats. 
**- Wells with lymphocytes also contained MEM with 20% FCS. 
***- Percent specific lysis with lymphocytes alone, CMI(L), or with im¬ 
mune serum in addition to lymphocytes, CMI(S), was calculated 
as described in text. 
k- Specific cytotoxic activity significant by Student's t test (p .05) 
h- Significant "helper" serum activity (p<.05); i.e., CMI(S) CMI(L) 
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Figure 12 
CMI(L) and CMI(S) in Untreated Animals 
through the Course of Disease 
- CMI(L) 
~ CMI(S) 
* 
/tumor cells in experimental well 
l tumor cells in control well Specific Lysis, % = 100 X 
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statisti cally significant (p < .05) on days 21 , 28, 34, 39, and 48. 
There appeared to be a biphasic nature to the lymphocyte response, 
with relatively high levels of CM I (L) on days 21 and 28, much lower 
levels on days 31 and 34, and a return to higher levels on days 39 and 
48. Maximum levels of CMI(L) appeared on days 21 and 39, at which 
times there were 56 and 48% specific lysis, respectively. 
Further tests of tumor-specificity in the cytotoxic response of 
immune lymphocytes were performed using normal rat fibroblasts and a 
xenogeneic mouse tumor line as target cells for the assay. At no time 
were lymphocytes from tumor-bearing animals cytotoxic for these cells 
when compared to wells containing normal rat lymphocytes. 
Serum Modification of CMI(L) in Untreated Animals: 
When serum obtained from tumor-bearing animals between 10 and 48 
days of age was added to wells containing immune lymphocytes, specific 
lysis (CMI(S)) was consistently increased. CM I (S) was statistically 
significant (p < .01) in every assay, indicating the cytotoxicity of 
immune lymphocytes and serum compared with their normal counterparts 
from uninfected animals. CMI(S) general ly followed the same biphasic 
course as CMI(L) in these untreated animals (Figure 12). 
Serum factors in untreated animals invariably increased the cyto¬ 
toxicity of immune lymphocytes compared with wells containing immune 
lymphocytes and medium alone; i.e., there were "helper" factors in 
these sera. When the difference between CMI(S) and CMI(L) was compared 
by the Student's t test, significant helper activity was found to be 

-90- 
present on days 14, 28, 31, 34, 39, and 48. It is noteworthy that, 
despite this helper activity, all untreated animals had progressively 
enlarging tumors at the time of assay. 
Because of the possibility that antibodies in immune serum might 
enhance the cytotoxicity of normal lymphocytes against MSV/WL cells, 
wells testing this anti body-dependent cellular cytotoxicity (ADCC) 
were included in all assays through day 28. No cytotoxicity above 
that of normal lymphocytes without serum was found, and this reaction 
mixture was not used in subsequent assays. 
CMI(L) in Animals Treated with 1 mg/kq/day Adriamycin: 
Specific lysis by immune lymphocytes from animals treated with 
the lower dose of adriamycin was demonstrated in animal groups tested 
from 22 to 48 days of age. These results are summarized in Table IV 
and depicted graphically in Figure 13. CMI(L) was statistically signi¬ 
ficant compared with control wells (p < .05) on days 26, 35, and 42. 
As seen in untreated animals, CMI(L) in these adriamycin-treated 
animals revealed a maximum of activity between 20 and 30 days of age. 
After a maximum specific lysis of 61% on day 26, lymphocytes in treated 
animals likewise showed diminishing activity by day 35. Unlike the 
untreated animals, however, in which CMI(L) subsequently returned to 
early high levels around day 40, cytotoxicity continued to diminish 
in this treatment group. Two possibly significant differences existed 
between the assays for untreated as compared to treated animals on the 
last two days of assay when the CMI(L) continued to decrease: (1) as 
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Table IV 
Activity of Immune Lymphocytes and Serum from Animals 
Treated with 1 mg/kg/day Adriamycin versus MSV/WL cells 
Age 
(days) 
Cells in 
Control 
Wei 1 s 
* 
Cells in Experimental 
Wei 1 s 
CMI(L) 
*** 
% 
CMI(S) 
*** 
% 
Status 
+ 
Lymphocytes 
Alone 
** 
With Immune 
Serum 
15 140±1 144±12 104±11 -2.8 26 P 
22 88±6 83±3 84±6 5.7 4.5 P 
26 46±3 18±8 29±2 61 37 P 
35 67±6 55±4 67±5 18 0 P 
42 224±4 201±8 191 ±6 10 15 R 
48 11 5±3 112±10 99±7 2.6 14 R 
*-All control wells contained lymphocytes and serum from uninfected 
rats. 
**- Wells with lymphocytes also contained MEM with 20% FCS. 
***- Percent specific lysis with lymphocytes alone, CMI(L), or with im¬ 
mune serum in addition to lymphocytes, CMI(S), was calculated 
as described in text. 
+- "P" refers to a progressor animal; "R" in these assays refers to 
an animal bearing a tumor diminishing in size. 
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Figure 13 
CMI(L) and CMI(S) in Animals Treated with Adriamycin, 
1 mg/kg/day, i.p., through the Course of Disease 
100 
90 
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opposed to assays of untreated animals and the earlier assays of this 
treatment group in which three animals' lymphocytes and sera were pooled, 
the same one animal 's effector cells and sera were used for the last 
two assays, collected from peripheral blood obtained through tail nicks; 
and (2) this animal, although tumor-bearing, was considered a regressor 
rat. The remainder of the rats assayed in this group, as well as all 
of the untreated animals, were demonstrated to have progressively 
enlarging tumors. 
Serum Modification of CMI(L) in Animals Treated with the Lower Dose of 
Adriamycin: 
Serum from animals treated with the lower dose of adriamycin had 
a variable effect on CMI(L) at different times during the course of 
disease. Similar to the effects of serum from untreated animals early 
in the disease course, CMI(S) on day 15 was significantly higher than 
CMI(L) in this treatment group (p < .02). This was three days after 
the completion of the course of treatment with adriamycin. 
On days 22, 26, and 35, however, serum factors from these treated 
animals partially blocked the cytotoxicity of immune lymphocytes. On 
the latter two of these three days, blocking activity was significant 
(p < .05). 
Finally, on the last two days of assay, serum factors again en¬ 
hanced the cytotoxicity of reaction mixtures containing immune lympho¬ 
cytes. This helping activity, however, was not statistically signi- 
fi cant (p < .20). 
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CMI(L) in Animals Treated with 2 mg/kg/day Adriamycin: 
Cytotoxicity for MSV/WL by lymphocytes from tumor-bearing animals 
treated with the higher dose of adriamycin was seen in all groups tested 
from 15 to 46 days of age. These data are summarized in Table V and 
illustrated graphically in Figure 14. As evaluated by the Student's t 
test, specific lysis was significant on days 22, 26, 40 and 46. 
The course of CMI(L) in this treatment group was almost identical 
to that seen in the untreated animals, revealing a similar biphasic 
pattern. Maximum cytotoxicity occurred on days 22 and 46, each of 
these showing a specific lysis of 50%, and these points were symmetri¬ 
cal ly distributed about a nadir at 33 days, at which time specific 
lysis was 1.5%. In contrast to assays in the group treated with lower 
dose adriamycin, the final two days of assay in this group revealed 
a return to high levels of cytotoxicity. 
Serum Modification of CMI(L) in Animals Treated with the Higher Dose 
of Adriamycin: 
As seen in animals treated with adriamycin at 1 mg/kg/day, serum 
from animals treated with the higher dose adriamycin had a course- 
related variable effect on CMI(L) (Figure 14). As in both other 
experimental groups, CMI(S) was higher on day 15 than CMI(L) in this 
treatment group. 
In addition, this helper serum effect converted to blocking acti¬ 
vity on days 22, 26, 33, 40, and 46. Blocking activity was statistically 
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Table V 
Activity of Immune Lymphocytes and Serum from Animals 
Treated with 2 mg/kg/day Adriamycin versus MSV/WL Cells 
Age 
(days) 
Cells in 
Control 
Wei 1 s 
* 
Cells in Experimental 
Wei 1 s 
CMI(L) 
*** 
% 
CMI(S) 
'k'k'k 
% 
Status 
+ 
Lymphocytes 
A1 one 
** 
With Immune 
Serum 
15 140±1 138±13 116±13 1 .4 17 P 
22 88±6 44±1 2 59±14 50 33 P 
25 46±3 28±1 30±7 39 35 P 
33 67±6 66±8 41 ±14 1.5 -6.0 P 
40 224±4 139±6 184±11 38 18 R 
45 115±8 57±4 77+6 50 33 R 
*- All control wells contained lymphocytes and serum from uninfected 
rats. 
**- Wells with lymphocytes also contained MEM with 20% FCS. 
***- Percent specific lysis with lymphocytes alone, CMI(L), or with im¬ 
mune serum in addition to lymphocytes, CMI(S), was calculated 
as described in text. 
+ - "P" refers to a progressor animal; "R" in these assays refers to 
an animal bearing a tumor diminishing in size. 
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Figure 14 
CMI CL) and CMI(S) in Animals Treated with Adriamycin 
2 mg/kg/day, i.p., through the Course of Disease 
- CMI(L) 
- CMI(S) 
* Specific Lysis, % = 100 X 
tumor cells in experimental 
tumor cells in control well 
wel 1 
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significant on two of these days (p < .01). As shown in Figure 14, 
throughout the course of disease, serum activity paralleled CMI(L) in 
its biphasic pattern. 
In contrast to serum from animals in the groups treated with low 
dose adriamycin, serum in this treatment group continued to block CMI(L) 
activity on the last two days of assay. However, effector cells and 
sera were likewise obtained from tumor-bearing regressor animals. 
Brief Summary of CMI(L) and CMI(S) in All Experimental Groups: 
Specific lysis of MSV/WL by lymphocytes from animals in all exper¬ 
imental groups was seen from approximately two to seven weeks of age. 
Although all lymphocytes were tested against a single homogeneous 
tumor line, assays of untreated animals were performed at a different 
time than assays of adriamycin-treated animals, and therefore strict 
statistical comparison of levels of CMI(L) on particular days between 
the groups is not considered entirely valid. Nevertheless, levels of 
CMI(L) were similar in all animal groups at comparable ages, and the 
maximum lysis observed in untreated animals (56% on day 21) was very 
similar to that seen in animals treated with the lower dose of adria¬ 
mycin (61% on day 26) as well as the higher dose (50% on days 22 and 
46). Thus, in general, there appeared to be no significant depression 
of cell-mediated immunity by adriamycin at doses which caused statis¬ 
tically significant increases in MST and the number of regressor 
animals in the treated groups. 
In addition, patterns of CM I (L) during the course of disease were 
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similar in the three experimental groups. An early peak of activity 
occurred in all groups around days 21-26, followed by a diminution of 
specific lysis by days 31-33. This was followed by a second peak of 
activity around days 39-40 in animals untreated or treated with the 
higher dose of adriamycin, whereas in animals treated with the lower 
dose, CMI(L) continued to fall. 
In contrast to CM I (L), significant differences occurred in the 
patterns of CMI(S) in the three groups. Whereas only helper serum 
factors were present in untreated animals, early helper activity in 
treated animals converted to blocking activity by day 22. This per¬ 
sisted in animals treated with higher doses of adriamycin, while in 
animals treated with the lower dose, a modest reversion to helper 
activity was seen on days 42 and 46. 
H. Cel 1 -mediated Immunity and its Serum Modification as Measured 
by an Assay Using Isotopic Labelling 
On every day that a visual assay was performed, a cytotoxicity 
assay using radiolabelled target cells was also attempted in order to 
find an ideal isotopic method that closely correlated to the results 
of the standard visual evaluation. In addition, however, visual count¬ 
ing of the remaining target cells is cumbersome, time-consuming, and 
221 233 
vulnerable to subjective interpretation. * The use of a method 
involving isotopic release by killed target cells minimizes this sub- 
jecti vi ty. 
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Several types of assay were attempted which were designed to ful¬ 
fill the following criteria of an ideal isotope, which should: (1) be 
incorporated and permanently bound to the target cell, preferably by 
a known metabolic pathway; (2) be released immediately at cell death; 
(3) not be reutilized by the remaining target cells; and (4) be incor¬ 
porated into targets in sufficient quantities to permit clear differ- 
116 
entiation of samples from background radiation levels. 
3 3 Methods were used in which H-thymidine or H-proline were added 
prior to incubation of the reaction mixtures ("pre-labelling" methods) 
or after target-effector cell incubation was completed and effector 
cells removed ("post-" or "pulse-labelling" techniques). A variety 
of harvesting techniques to remove and isolate remaining target cells 
were also attempted. 
The post-label assay perhaps most closely reflects the cytotoxi¬ 
city and pro! iferation-inhibi tion which is characteristic of target 
cell measurements in the visual assay. In addition, short term 
"pulse-labelling" minimizes high levels of spontaneous loss of the 
tracer and avoids the difficulties of long-term radiation injury to 
221 the target cells occasionally seen in pre-label assays. 
3 
Pulse-labelling with H-thymidine produced results which most 
closely correlated with those of the visual assay in this rat model 
for osteosarcoma. Tritiated thymidine has been used in other experi¬ 
mental in vitro assays"116,165, and in this system effected counts 
approximating 0.7-1.0/MSV/WL cell/minute. 
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The method of harvesting remaining target cells at the end of 
3 
H-thymidine incubation was found to be crucial, and the trichloro¬ 
acetic acid precipitation method (see Methods section) was found most 
effective. In addition, vigorous washing and removal of effector cells 
prior to the addition of the isotope was essential to prevent incorpor¬ 
ation of the tracer into effector lymphocytes. 
The results of a typical post-label assay with 3H-thymidine and 
their comparison to results of the visual assay performed on the same 
TABLE VI 
Comparison of Visual and Post-Label Isotopic Assays of Cell- 
Mediated Immunity in Adriamycin-Treated Animals 
Group Age 
(days) 
Control 
Wells,* 
Experimental 
Wells, cpm 
Isotope 
Assay 
Isotope 
Assay 
Visual 
Assay 
Visual 
Assay 
cpm Lympho¬ 
cytes 
Alone 
** 
Wi th 
Imm. 
Serum 
CMI(L) ■*•*■*• 
% 
CMI(S) 
■kkk 
% 
CMI(L) 
% 
CMI(S) 
% 
Adr. 
1 mg/kg/d 48 565±17 584±7 501 ±18 -3.4 11 2.6 14 
Adr. 
2 mg/kg/d 46 56 5±17 302±9 367±38 47 35 50 33 
*- All control wells contained lymphocytes and serum from unin¬ 
fected rats. 
**- Wells with lymphocytes also contained MEM with 20% FCS. 
***- Percent specific lysis with lymphocytes alone, CMI(L), or 
with immune serum in addition to lymphocytes, CMI(S), 
was calculated as described in text. 
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day are surrmarized in Table VI. In brief, they show levels of CM I (L) 
and CM I (S) on days 45 and 47 post-infection in animals treated with 
2 mg/kg and 1 mg/kg adriamycin, respectively. CMI(L) and CMI(S) con¬ 
sistently differed by only 2-5% between the visual and radiolabel 
assays. These differences are within experimental error. 
I. Cytotoxic Antibody Response as Measured by a Microcytotoxicity 
Assay 
A modification of the micromethod of Kaliss^ using ^Cr-release 
by killed target cells was employed to measure cytotoxic antibody re¬ 
sponses during the course of disease. LSTRA tumor cells were used as 
target cells for this assay, and each cell incorporated approximately 
51 o 0.15 cpm of Cr after a 5 hour incubation at 37 C. Supernatants con- 
51 
taining released Cr were collected after centrifugation of the target- 
effector cell solutions. In early assays nonspecific lysis of cells 
was high (approximately 25% in control wells), and this was attributed 
to an unnecessarily vigorous centrifugation rate. When centrifugation 
rates were decreased to 800 rpm for 10 minutes, lysis in control wells 
diminished to an acceptable 10-15% background level. 
Heat-inactivated serum obtained at six times from animals nine to 
41 days post-inoculation and stored at -70°C showed no detectable titers 
of cytotoxic antibody. Sera from treated and untreated animals alike 
produced the same negative results. All wells were tested in dupli¬ 
cate and all experiments were performed twice. In addition, the micro¬ 
method detected cytotoxic antibody levels to leukemia L-1210 cells, 
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used as a positive control. 
LSTRA cells have been effectively employed as target cells to de¬ 
tect cytotoxic antibody in the serum of mice bearing MSV-induced tu- 
245 
mors. However, LSTRA cells are perhaps not as sensitive to iirmune 
cytolysis as are some other MSV-related tumors used as targets for 
181 
various in vitro assays. In the present study, no attempt was made 
to use other target cells for this assay, and no other assays measuring 
antibody-mediated cytolysis were employed. 
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IV. Discussion 
A. MSV-Induced Rat Osteosarcoma as a Model of the Human Disease 
While animal models of human malignancy must always be regarded 
with some skepticism, experimental systems which closely resemble their 
human counterparts can be extremely useful in further understanding the 
human disease and its response to various therapeutic modalities. ^ 
Important characteristics requiring comparison include etiology (where 
this is known), histology, biological course, immunological charac¬ 
teristics, and response to therapy. An initial report from Drs. Fried- 
laender and Mitchell here at Yale suggests that the MSV-induced osteo¬ 
sarcoma in Wistar-Lewis rats may be one such valuable model of the 
human disease. A major goal of the present investigation has been to 
further document the extent of the resemblance of this model to human 
osteosarcoma. 
Osteosarcoma is primarily a disease of young people, originally 
localized most often to the long bones of the lower extremities, and 
rapidly progressing to pulmonary metastases and death. Pulmonary 
metastases mark a definitive point in the course and therapy of this 
particular malignancy. 
Until recently, a variety of therapeutic modalities designed to 
prevent pulmonary metastases or effect their regression have been en¬ 
tirely unsuccessful, causing no significant increase in the 20% five 
year survivals effected by surgery alone. Recent chemotherapeutic 
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approaches using adriamycin have delayed (or prevented) the appearance 
of pulmonary metastases post-operatively, caused a 40% incidence of 
metastatic regression, and most likely significantly prolonged survival. 
A wealth of data exists to support a viral etiology for osteo¬ 
sarcoma in man, including immunological studies revealing a common anti¬ 
genicity to a variety of histological types of sarcomata. Immunologic 
studies are now being directed to clarifying the specific components 
of the immune response which are responsible for tumor progression or 
regression in vivo and in vitro. Preliminary knowledge along these 
lines has already been successfully exploited in the immunotherapy of 
osteosarcoma in man. 
Previous models of osteosarcoma have included spontaneous malig¬ 
nancies, and tumors induced by radiation, chemical carcinogens and 
oncogenic viruses in a multitude of animal species. While the spon- 
243 
taneous canine osteosarcoma is a most valuable model system, it is 
or o 
expensive and, due to its rarity, is not generally available. In 
view of the evidence for a viral etiology of the human disease, it is 
important that an experimental model of osteosarcoma be induced by a 
virus. The MSV-induced rat tumor fulfills this prerequisite. 
In addition, intra-tibial inoculation of MSV has produced, with 
excellent reproduci bil i ty, a tumor which is initially localized to the 
lower extremity of the infected animal. As opposed to other MSV-induced 
rat osteosarcomata caused by intravenous or interperitoneal administra¬ 
tion of the virus, the predictably localized tumor in the present system 
is a lesion which is accessible to observation, excision, and local 
radiotherapy or immunotherapy. 
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Like the other MSV-induced rat sarcomata, however, the lesion viewed 
microscopically is invariably osteogenic in nature. This is in notable 
contrast, as already mentioned, to the myosarcomatous nature of MSV- 
induced tumors in mice. Histologically, the primary tumors in rats 
revealed the same growth patterns and variability as their human counter¬ 
parts, with different areas within the lesions showing a predominance 
of malignant fibroblastic, cartilaginous or osteogenic tissue. Micro¬ 
scopic sections and radiographs alike documented the typical perio¬ 
steal elevation and cortical destruction caused by the tumors. 
Another unique characteristic of the rat osteosarcoma is its pro¬ 
pensity for metastasis. Previous experimental tumors have not readily 
metastasized, and their distribution of metastases have not been com- 
26 2 parable to the human disease. The preliminary experiments of Fried- 
laender and Mitchell documented the occurrence of metastases in the 
rat model, and these were most frequently observed in the lungs of 
infected animals.^ These early studies, however, made no attempt to 
document the incidence of metastatic lesions. 
That the ability to metastasize is of fundamental importance is 
obvious when considering the aggressive metastatic nature of osteo¬ 
sarcoma in man, and the pivotal role of pulmonary metastases in direct¬ 
ing therapy. It is assumed that hematogenous micrometastases are 
present in most patients at the time of diagnosis, and clinically 
detectable pulmonary metastases are present in approximately 10% of 
patients before therapy is begun. Autopsy data reveal a 95% incidence 
of pulmonary metastases in patients succumbing to their disease. 
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In contrast to the initial study117 which reported that pulmonary 
metastases were not evident until animals were four weeks of age, 
tumor-bearing rats in the present investigation had pulmonary meta¬ 
stases as early as 14 days post-infection. The incidence of pulmonary 
lesions did not vary significantly with age, as 89% of animals of all 
ages (either dying of tumor or sacrificed for assay) had metastatic 
pulmonary metastases. 
Osteosarcoma in man less frequently metastasizes to other loca¬ 
tions, including other long bones (14%), liver (8%), and lymph nodes 
(30-40%). In the rat model only one long bone metastasis was observed 
115 in the original study of 98 animals , and no bony metastases were 
observed in 22 untreated animals during the present experiments. Hepa¬ 
tic lesions considered suspicious for the presence of metastatic tumor 
were seen in 50% of tumor-bearing animals. Lymph nodes were grossly 
invaded by tumor in approximately 10% of the animals, and no metastatic 
lesions were observed in the 26 spleen specimens examined. 
Histologically, metastases were most frequently pleomorphic, 
undifferentiated sarcomas, with no apparent bone or cartilage-forming 
activity. Early lesions in all organs were scattered diffusely through¬ 
out the parenchyma, consistent with the hematogenous nature of their 
dissemination; whereas more advanced metastases in lung and lymph 
nodes were well circumscribed and nodular. 
In general then, the incidence, distribution, and histology of 
metastases in this rat model of osteosarcoma are comparable in most 
respects to the metastatic patterns seen in the human disease. The 
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predilection of both tumors to early pulmonary metastasis is particularly 
significant. This aspect of the present model gives it a notable advan¬ 
tage over previous animal models of osteosarcoma. 
The course of disease in untreated animals was relentlessly pro¬ 
gressive, with rapid tumor growth and death usually by 20 days of age. 
Although two animals survived 64 days, there were no regressor animals 
in the untreated group. This is in contrast to the 22% incidence of 
regressors reported by Friedlaender and Mitchell Two reasons can 
be offered to explain this apparent discrepancy in the model. First, 
the 22% figure is undoubtedly a moderate overestimate of the proportion 
116 
of regressor animals. In the earlier study, the limbs of fully 30% 
of the rats could not be evaluated because the animals had been canni¬ 
balized after death by the mother rat or their siblings. Progressor 
116 
or regressor status was then determined on the remaining 68 animals. 
Cannibalism occurs only in the case of a dead animal, and animals dying 
in the present investigation all had progressively enlarging tumors. 
It is suspected, therefore, that the original method of analysis mini¬ 
mized the proportion of rats dying with growing tumors (progressors). 
Secondly, the batch of virus inoculum in the present study may 
have been somewhat more virulent (and perhaps unintentionally more 
concentrated) than the batch used by Friedlaender and Mitchell. Pre¬ 
liminary experiments revealed that the "aggressiveness" of the induced 
tumor (including frequency of progressors) was proportional to virus 
dose. Although identical doses were used in both studies, tumors were 
clinically apparent an average of three days earlier in the present 
investigation. Coupled with the absence of regressors in otherwise 
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identical groups of animals inoculated at the same age, this suggests 
a difference in viral potency in the two studies. 
A final noteworthy general feature of the rat model of osteosar¬ 
coma is its response to therapy with adriamycin. Administered intra- 
peritoneally after 90% of the tumors were palpable, adriamycin at doses 
of 1 mg/kg/day or 2 mg/kg/day for three consecutive days significantly 
reduced tumor size, prolonged median survival times, and increased the 
proportion of regressor animals. In the latter two respects, the 
lower dose of adriamycin appeared to be more effective than the higher 
dose. The sensitivity of this tumor to adriamycin chemotherapy is 
another characteristic shared by its human tumor counterpart. 
Summarizing these data, it is clear that the MSV-induced osteo¬ 
sarcoma in rats bears a striking similarity to human osteosarcoma. 
The present study has confirmed previous work describing the morpho¬ 
logical characteristics of the tumor and showing its progressive and 
metastatic course. In addition, this investigation has documented an 
incidence and distribution of metastatic disease comparable to that 
seen in man, and shown that this tumor is likewise responsive to treat¬ 
ment with adriamycin. The significance of the animals' immunological 
response to the tumor (discussed in the next section) further demon¬ 
strates the value of this model system in understanding and success¬ 
fully treating osteosarcoma in man. 
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B. The Immunobiology of MSV-Induced Tumors 
The science of tumor immunology has been greatly advanced during 
140 
the past decade by the discovery in 1964 of Moloney leukemia virus 
variants, later designated murine sarcoma virus-Moloney, or MSV. Since 
1964, a vast literature has arisen documenting the biology of tumors 
induced by this virus in mice, hamsters and rats. In particular, the 
attention and scrutiny of tumor immunologists to these systems have 
been drawn by the observation that MSV-induced tumors will often spon- 
102 taneously regress -- a phenomenon unique to these systems. Sponta¬ 
neous regression has been shown to be dependent on the dose of the 
virus, the age and strain of the host, and more importantly, the status 
102 
of the host immunity. Both cellular and humoral immunity have been 
shown to be significant in effecting regression in various MSV systems, 
with cellular responses generally considered the more important of 
the two.103’104 Precisely which cells (T-cells, B-cells, macrophages, 
"normal" vs. specifically immune cells) and which serum factors (cyto¬ 
toxic, cytophilic, "unblocking", or "arming" antibodies) are most res¬ 
ponsible for tumor regression appears to vary by animal species or 
strain,169,181 as well as by the specific assays used.106 In addition, 
the magnitude of the response of particular inrnune factors may vary 
during the course of the disease, and this time-related variation may 
differ in different animal strains or species. 
The above variabilities notwithstanding, there is sufficient 
commonality to the immunobiology of the several MSV systems to warrant 
a well-defined comparison of one model to the next. In this context. 
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a brief discussion of the more intensively investigated MSV systems 
seems pertinent. It is hoped that this discussion will put the results 
of the present investigation in a more proper perspective in the other¬ 
wise overwhelming literature of MSV-induced tumors, and tumor immuno¬ 
logy in general. 
Immunobiology of MSV-induced Tumors in Mice: 
Newborn mice inoculated with MSV invariably develop tumors within 
10 days which usually grow progressively and kill the animals by two 
weeks of age.102’^" Older mice are equally susceptible to tumor 
induction by MSV,but if inoculated after 4 weeks of age will develop 
tumors which virtually always regress. Immunosuppression of adult 
mice by X-i rradiation, neonatal thymectomy, ALS or cortisone treatment, 
or chemotherapy with cyclophosphamide or daunomycin, causes a signifi- 
, , . . , , . . 45,100,102,185,286 
cantly decreased incidence of tumor regression. 
Early reports emphasized the significance of tumor-specific cel- 
lular mechanisms in effecting tumor regression. While some 
of these preliminary studies were lacking in the technical sophisti¬ 
cation required to demonstrate humoral immunity, cellular res¬ 
ponses were felt to be beneficial to tumor regression, and humoral 
mechanisms were thought to be unimportant. Particularly striking 
was the decreased incidence of adult regressors in groups which had 
185 been neonatal ly thymectomi zed , and the infiltration of regressor 
103 but not progressor tumors with massive numbers of mononuclear cells. 
Basically two differing patterns of cellular responses during the 
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course of disease have been reported by different investigators. 
141 143 Early studies by the Hellstroms * emphasized the similarities 
between cellular activities in progressor and regressor animals, in 
which lymphocyte-mediated antitumor responses remained at high levels 
throughout the disease course. More recent investigations have studied 
the time course of the cellular response in greater detail and have 
arrived at a different conclusion.^9,181 ,lo6 ie using a vari¬ 
ety of mouse strains (usually BALB/c or their F-j hybrids with C57BL/6 
strains), these reports are remarkable in their similarity to one 
another. In general, they have reported a maximum of cellular acti¬ 
vity approximately two weeks after virus administration. After about 
three weeks, cellular cytotoxicity diminishes in both progressor and 
regressor animals. Most studies have indicated that progressor animals 
have lymphocytes that are somewhat less cytotoxic than their regressor 
counterparts, and that the diminution of cytotoxicity after three 
weeks occurs more rapidly in regressor animals. The patterns of cel¬ 
lular activity in both groups, however, are very similar. 
Different populations of effector cells appear to be acting at 
various stages during the course of disease. Lamon and his associates 
have studied this aspect of MSV-tumor-speci fic immunity in great detail 
by a variety of immunological techniques."^7,179 specifically, T-cell 
reactivity appears to be most significant before 30 days post-infection, 
with maximum cytotoxic levels occurring between days 10 and 20. After 
30 days, however, T-cell responses are negligible, and cytotoxicity 
is dependent on non-T lymphocytes. 
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Dating back to the earliest reports of the MSV models, humoral 
immunity was considered to be unimportant in mediating tumor regression. 
103 
Fefer et al. reported that mice inoculated with Moloney sarcoma cells 
after incubation with immune serum developed as many tumors as mice 
inoculated with Moloney sarcoma cells incubated with normal serum. 
Pre-incubation of tumor cells with immune spleen cells, however, signi¬ 
ficantly protected the animals against tumor induction. 
141 143 Furthermore, studies by the Hellstroms ’ showed that humoral 
factors could actually enhance tumor growth both in vivo and in vitro. 
These blocking factors were frequently found in the sera of progressor 
animals, while regressors most often lacked such blocking activity. 
Enhancement of tumor growth was first thought to be due to antibodies 
in the serum of progressors, and later was demonstrated to be mediated 
292 by antigen-antibody complexes. Suffice it to say, at this point, 
that enhancement does occur, and that it has been convincingly demon¬ 
strated not only in MSV systems, but in other experimental tumor 
models and man as well. A more detailed evaluation of enhancement 
will be made in subsequent sections of this Discussion. 
In addition to the blocking effects of certain serum factors, 
more recent investigations have demonstrated tumor-inhibi tory factors 
in the serum of animals bearing MSV-induced tumors. 100,126>143,177,178, 
185,246,255,156,193,312 TU , . ... .. , , These factors are antibodies, as shown by 
immunofluorescence, neutralization, cytotoxicity and fractionation 
techniques. That they can be significant in vivo has been demonstrated 
246 by the studies of Pearson et al. , who reported that pretreatment 
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of recipient mice with regressor serum before tumor challenge resulted 
in a significantly higher incidence of regressor animals (than pretreat¬ 
ment with normal serum). 
Tumor-inhibitory antibodies may be divided into those which are 
complement-dependent in their activities, and those which act indepen¬ 
dent of complement. Complement-dependent cytotoxic antibodies have 
177 178 312 been demonstrated in the sera of both MSV tumor-bearing animals 5 ’ 
332 
and osteosarcoma-bearing humans. Significant titers of cytotoxic 
antibodies were present in 70% of regressor, and interestingly, 24% 
312 
of progressor animals studied by Tamerius and Hellstrom. 
Complement-independent antibodies include a much larger group of 
globulins under a variety of names with overlapping activities. "Arm¬ 
ing" antibodies, which aid in (normal, non-sensitized) cellular cyto¬ 
toxicity, have been repeatedly found in MSV systems by a number of 
177 179 255 256 investigators. ' * * It was primarily this group of antibodies 
which was responsible for the late B-cell activity (or, more precisely, 
non-T cell activity) in MSV systems referred to in the reports by 
177 179 255 256 Lamon et al . 5 Pollack and her associates 5 have reported 
such "synergistic cytotoxicity" in 75% of sera from MSV tumor-bearing 
animals. Significantly, serum from progressor animals armed normal 
lymphocytes as well as serum from regressors, and cytotoxi ci ty was 
often demonstrable with sera diluted as highly as 1:1280. 
Factors in the serum of regressor animals were found to "unblock" 
the blocking effects of progressor sera in studies by the He 11 stroms.^ 
Likewise, tumor-inhibitory macrophage "cytophilic antibodies" have been 
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213 230 
reported in non-MSV tumor systems and man. ’ The relationships 
of "cytophilic antibodies" and "unblocking antibodies" to "arming 
antibodies" remain to be determined. 
Blocking and "helping" activities often exist simultaneously in 
255 256 293 
the same serum. ’ ’ In addition, predominantly blocking acti- 
293 
vity may be seen in regressor animals , while mainly helping activity 
1 I r ore O £ 919 
may be seen in progressors. ’ ’ ’ The net result of serum 
293 factors on in vitro cytotoxicity may depend on animal species , con- 
. .. ,, . 255,256 ,293 .. , .. 1 77,178,255,256 ,293 
centration effects , or the stage of disease. ’ ’ ’ 
Finally, it is clear that in vi vo and i n vi tro tumor destruction in 
MSV-induced malignancies is mediated by a balance of mostly beneficial 
cellular, and variably beneficial serum mechanisms. 
Immunobiology of the Present MSV-induced Tumor System: 
In its general immunologic features, the rat model of osteosar¬ 
coma is very similar to MSV-induced tumors in mice. Neonatal ly MSV- 
inoculated rats develop progressive tumors, and the incidence of re¬ 
gressor animals is inversely proportional to the dose of virus admini- 
116 
stered. The present section will discuss the levels and course of 
cellular and humoral immunity in the untreated animals of this inves¬ 
tigation, and relate these results to the findings in other experi¬ 
mental systems. 
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Cellular Responses - CMI(L): 
There were two significant aspects of the cellular response of 
untreated animals to MSV/WL cells: (1) cellular cytotoxicity was found 
to be tumor-specific, and present in all animal groups tested from 14 
to 48 days of age; and (2) the course of cellular cytotoxicity was bi- 
phasic in nature. 
The first finding -- that of tumor specificity in the cytotoxic 
response -- was anticipated. It is characteristic of virally-induced 
tumors in general, and MSV-induced tumors in particular, to possess 
tumor-specific antigenic determinants. The fact that tumors are anti- 
genically dissimilar from normal tissues serves as the foundation for 
the science of tumor immunology. Tumor antigenicity, in Ehrlich's 
words, "represents the key to carcinoma", and established the basis 
of Thomas and Burnet's theory of immune surveillance. 
In the present invest!gation, tumor antigenicity was tested in 
two ways. First, lymphocytes from non-inoculated age-controlled rats 
were tested against MSV/WL cells and found to be unreactive. These 
lymphocytes were not primed to "recognize" the tumor cells as foreign. 
Second, lymphocytes from tumor-bearing rats were tested against syn¬ 
geneic fibroblasts and xenogeneic tumor cells, and these too were un¬ 
reactive. The lack of cytotoxicity against the mesenchymal control 
is of particular importance, in that this finding supports the evidence 
that tumor antigens in this system are virus-speci fi c,rather than 
organ-speci fic. 
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That the pattern of cellular response to MSV/WL was biphasic was 
somewhat surprising. This pattern was clearly evident throughout the 
course in the untreated animal group as well as the group treated with 
the higher dose of adriamycin. It was "incomplete" in the group 
treated with the lower dose of adriamycin in that a final return to 
high cytotoxic levels was not observed. It is pertinent to this dis¬ 
cussion that CM I (S) in the three groups followed a similar biphasic 
pattern. 
Specifically, after very early low levels of cytotoxicity, tumor 
cell lysis by lymphocytes reached a maximum level around 21-26, fol¬ 
lowed by a rapid decline in activity by days 31-33. This was in turn, 
followed by a second peak of cellular response around days 39-40. 
The very early latency and increase in cellular response is 
easily understood and consistent with immune reactivity in many other 
tumor models"'77,179,181,186,240, anc| immune reactions in general. In 
these experimental systems, cytotoxic activity first appears when 
growing tumors are already palpable. Several models have been evalu- 
186 
ated by Led ere et al . , and this relation between tumor growth and 
the appearance of cytotoxic lymphocytes was found in all systems 
tested, whatever the latencies of the tumors (up to 65 days in late 
MSV tumors). This has suggested that a threshold number of tumor cells 
is required to trigger the immunologic response. Thereafter the kine¬ 
tics of the immune reaction may vary with the biology of the specific 
tumor-host interaction. 
Likewise, the fall of immune reactivity around days 31-33 is con- 
1 8 240 
sis tent with several other tumor models ’ , including the MSV-induced 
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malignancies in mice. 77-179,181 ,185 ,186 ^ -j i e ^he specific time course 
differs, cellular reactivity in BALB/c mice bearing MSV-induced tumors 
follows a similar phasic pattern, attaining a peak of cytotoxicity at 
approximately 14 days, followed by a progressive decline by around 
three weeks. It can only be speculated that the differences in exact 
time sequence in the two systems reflect a difference in species and a 
slightly different tumor biology and course in the two hosts. 
It has also been demonstrated with transplanted tumor cells in 
240 ] g 
the Gross and attenuated Rauscher virus systems that measurable 
in vitro cellular immunity develops early after transplantation, but 
rapidly disappears as tumor growth proceeds. In the latter system, 
cellular immunity returned after surgical tumor removal. 
While it is easy to cite the similarities in the phasic responses 
of the various models, it is much more difficult to explain why a 
decline in cellular reactivity should accompany tumor growth. Lamon 
179 
et al. suggest four possible explanations, which are here briefly 
enumerated and expanded: (1) Tumor cells may be protected from the 
141 143 tumoricidal effects of immune lymphocytes by blocking antibodies. ’ 
While this mechanism is possible, in this investigation only "helper" 
effects in the serum of untreated animals were observed, making 
significant antibody-mediated blocking unlikely. (2) Immune lymphocyte 
aggregation at the tumor site in vivo in growing tumors may diminish 
in vitro cellular reactivity.108,210 s -js certainly supported 
by the findings of Fefer et al J0°’^ 0f intense lymphocytic infil¬ 
trates seen in growing MSV-induced tumors. A correlate of this type 
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of explanation is reported by Alexander et al 7, who have shown that 
a growing tumor (a primary chemically-induced sarcoma in rats) induces 
a specific blockade of the regional lymph nodes, preventing the dis¬ 
semination of tumor-specific immunoblasts. (3) Immune lymphocytes 
may be inactivated by antigen overload. This explanation is particu¬ 
larly attractive, and is supported by numerous studies with soluble 
7 17 ?R7 
and tumor-specific antigens. ’ ’ ’ It has been clearly demon¬ 
strated that tumor associated antigens, in one form or another, may 
escape from tumor cells and become detectable in the serum of tumor- 
318 7 bearing animals. In the study by Alexander et al. just cited, 
the lymph node blockade was attributed to the persistent exposure of 
the nodes to antigen being shed by the tumor. 
MSV-induced tumors are known to readily shed such antigens, as 
178 185 
well as virus particles. * In general, with advancing tumor growth, 
65 the amount of antigen released increases rapidly. Thus, in the pre¬ 
sent investigation, decreased immune reactivity (both CMI(L) and CMI(S)) 
is well correlated with a period of rapid tumor growth (Figures 5 and 
12) in the untreated animals. 
(4) Finally, Lamon et al . postulate that the vi remi c state itself 
may produce depressed lymphocyte reactivity. Since MSV-induced tumors 
104 185 
shed infectious virus * , the viremic state of the animal and the 
presence of vi rus-neutrali zing antibodies may be quite variable influ¬ 
ences on the lymphocyte reactivity to this antigen. 
Only the first two parts of the CMI(L) pattern have been discussed 
to this point. The latency and rise in cellular reactivity are readily 
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explained by a "threshold" principle. The subsequent fall in reac¬ 
tivity in vitro may be explained by a variety of phenomena, including 
lymphocyte aggregation (either at the tumor site or in lymph nodes) 
and antigenic overload (by released tumor antigens or virus particles). 
While a combination of these events may be occurring simultaneously, 
evidence has been presented to support the antigen-overload hypothesis 
in this MSV system. 
The final return to high cytotoxic levels is more difficult to 
explain and has no precedent in the literature. While it would be con¬ 
venient to attempt an explanation representing the reversal of the 
above phenomena known to depress cellular reactivity, late high levels 
of cytotoxicity occurred in both regressor and progressor groups of 
animals, the latter bearing continually enlarging tumors. The reversion 
to elevated levels of tumoricidal activity in attenuated Rauscher virus 
18 
systems after tumor excision has been previously noted. In this sys¬ 
tem, however, antigen load was immediately diminished, allowing cellu¬ 
lar responses to return to their early high levels. 
Support for a similar biphasic immune response is present in stu¬ 
dies of humoral immunity in both MSV and Gross virus-induced tumor 
systems While the biphasic pattern in the MSV tumor system 
appeared only in regressor animals, a clear biphasic response was seen 
in some progressor rats in the Gross virus system. 
Considerable evidence suggests that factors operating to depress 
cellular reactivity also mediate humoral immune depression. 
Conversely, it seems fair to assume that factors (or the absence of 
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same) allowing the expression of humoral immunity may likewise allow 
the expression of cellular responses. In this context, although a 
biphasic cellular response to tumor antigens is to date unreported, 
the comparison to similar humoral data seems unwarranted. No further 
explanation of the phenomenon can be offered at this time. 
Although effector cells in this investigation have been referred 
to as lymphocytes, the effector population was in fact a more hetero¬ 
geneous group of cells, including macrophages as well as T-cells and 
B-cells. After Ficol 1-Hypaque density gradient centrifugation, the 
effector population was found to contain an average of 921 lymphocytes, 
4% monocytes, and approximately 4% polymorphonuclear leukocytes. 
59 177 179 Consistent with previous investigations in MSV systems ’ * , 
it is assumed that T-cells played a prominent role in the in vitro 
cytotoxic reactions. The role of antibody-dependent cellular cyto¬ 
toxicity (ADCC) was tested in untreated animals through their first 
28 days and found not to contribute to tumor cell lysis. While this 
is suggestive for the unimportance of ADCC in this investigation, 
previous studies in MSV-mouse systems have shown that ADCC does occur, 
but that it is not quantitatively significant until approximately 30 
177 179 days post-infection. ’ The presence of active ADCC in the rat 
model of osteosarcoma after 28 days cannot therefore be ruled out. 
Further studies to determine the precise effector cells active during 
the course of disease in this system are clearly indicated. 
' 
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Humoral Responses - CMI(S): 
A significant finding accompanying the study of in vitro humoral 
activity was that serum factors in untreated animals were exclusively 
"helper" in nature; that is, throughout the course of disease in pro- 
gressor animals, serum factors increased the cytotoxicity of reaction 
mixtures over those containing effector cells alone. This was a 
somewhat unexpected finding, in that the more usual pattern observed 
in MSV mouse tumor systems is that progressor sera block, while re¬ 
gressor sera increase, cellular cytotoxicity. In addition, the pre¬ 
liminary study by Friedlaender and Mitchell^'7 in this rat model re¬ 
ported CMI(S) findings apparently consistent with those seen in MSV 
mouse systems. The present results are readily explained when the 
nature of CMI(S) is considered and the earlier results in this model 
are more carefully scrutinized. 
Put simply, CMI(S) is an in vitro measure of the net result of 
factors in the serum potentially beneficial and/or deleterious to 
tumor cell proliferation. As noted earlier, there are several possi¬ 
bly different antibody populations in the serum of MSV tumor-bearing 
animals which may act independently or synergistically with cellular 
responses to kill tumor cells. Cytotoxic antibodies are complement- 
dependent, and therefore probably play no part in CMI(S) in the heat- 
inactivated serum of this investigation. This is further supported 
by the inability of this investigator to demonstrate the presence of 
cytotoxic antibodies in other in vitro assays. Nevertheless, several 
populations of complement independent antibodies, including "unblock¬ 
ing", "arming", and "cytophilic" antibodies are potentially significant. 
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The former two groups of gamma-globulins have been convincingly demon¬ 
strated in MSV tumor systems. While the inability of antibodies to 
arm normal lymphocytes through day 28 in this investigation might 
suggest the absence of significant ADCC, specific antisera may arm 
immune lymphocytes as wellJ'7'7’^ "Arming" antibodies may therefore 
have contributed to the helper effects of progressor sera in these 
assays. 
In addition, while the relationship between "arming" and "unblock- 
255 ing" antibody populations remains to be resolved , unblocking anti¬ 
bodies have been convincingly demonstrated by the Hellstroms in the 
141 
sera of MSV tumor-bearing mice. Unblocking antibodies may also 
have contributed to the helper effects seen in the present study. 
Macrophage cytophilic antibodies, and antibodies bound to MSV 
1 78 tumor cells observed by immunofluorescence techniques may have been 
significant. While cytophilic antibodies have not been tested in MSV 
systems, the presence of 4% macrophages in the effector population of 
the present investigation makes their a priori exclusion impossible. 
Whenever CMI(S) is greater than CMI(L), the quantitative activity 
of tumoricidal serum factors is greater than serum blocking factors. 
As noted previously, the correlation of tumor status with in vitro 
serum effects is not as clear in MSV models, or any models for that 
141 143 
matter, as originally proposed. * Blocking factors may be observed 
293 in regressor animals , while predominantly helping activity may be 
seen in progressors. ’ Rates of tumor growth ’ * * 
256,293 
and destruction, rather than a more absolute "tumor status 
k 
» 
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classification, may be most important in determining CM I (S). Like¬ 
wise, tumor-inhibitory or tumor-enhancing properties in vitro may be a 
result of concentration effects. Particularly pertinent in this regard 
293 
are the results of Skurzak et al. , who studied MSV-induced tumors 
in Fischer rats. In their studies, blocking was demonstrated in a 
regressor animal, and, in general, high concentrations of sera were 
tumoricidal, whereas highly diluted sera caused blocking. 
Finally, the apparent discrepancies between the earlier studies 
and the present investigation in the rat osteosarcoma model are mini¬ 
mized when the preliminary work is more carefully scrutinized. While 
blocking serum activity was present on days 32 and 34 post-infection 
in progressor animals, helper activity was clearly evident in progressor 
animals on days 25 and 37. In addition, blocking activity was ob¬ 
served in a regressor animal on day 65. It seems apparent that no 
broad generalizations about tumor status correlation with serum acti¬ 
vity can be made from these data. In contrast, the seemingly paradoxi¬ 
cal finding of helper activity in progressors was consistently observed 
throughout the course of untreated animals in this investigation. The 
specific nature of this helping activity remains to be determined. 
A second significant finding accompanies studies of CM I (S) -- 
consistent with cellular data -- showing a biphasic humoral response. 
The previous findings of a biphasic humoral response in the Gross 
virus and MSV mouse systems have already been cited. Again, the most 
attractive explanation for the mid-course nadir of inmune reactivity, 
almost precisely parallel in time to cellular depression, is antigenic 
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overloading. It is conceivable that all the antibody might be bound 
up in the form of anti gen/anti body complexes , which may not only 
depress cellular reactions, but block humoral activity as well. The 
other explanations offered for declining cellular reactivity apply also 
to humoral immunity, and may have contributed to the immune kinetics 
observed. 
The second peak in humoral activity seen in the Gross virus sys- 
tern represented a different globulin fraction (7S) than that observed 
in the first peak (19S). It is possible that the two peaks of humoral 
activity observed in the present investigation likewise represented 
19S and 7S fractions, respecti vely. Further studies are necessary to 
substantiate this possibility. 
C. The Dual Effects of Adriamycin 
Overview: 
As discussed earlier, anticancer drugs usually have immunosuppres¬ 
sive effects in addition to their tumoricidal actions. Immunosup¬ 
pression in the course of chemotherapy for neoplastic disease may be 
self-defeating, compromising host defenses often required to effect 
eradication of the last tumor cells. It is essential to understand 
which drugs are immunosuppressive, under what conditions of dose and 
schedule they may cause such immunosuppression, and which aspects of 
the tumor-immune response are most affected. When the import of given 
immunological responses to a particular malignancy are better under¬ 
stood, specific drugs which avoid depression of these responses may be 
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employed. When immunosuppression is unavoidable by an effective tumor- 
icidal agent, therapy in the future may be directed to non-specific or 
157 198 
specific reversal of this effect. ’ Intensive research efforts 
are now being aimed at making this theoretical possibility a reality. 
MSV tumor systems are models of human disease in which biological 
course and tumor-specific immune mechanisms have been increasingly well 
defined. This investigation has further explored the cellular and 
humoral responses in an MSV-induced rat model of osteosarcoma. Its 
consistent reproducibility makes it an excellent model to study the 
immunological effects in vivo and in vitro of anticancer agents. 
Major goals of the present study have been to evaluate the effi¬ 
cacy of adriamycin in treating tumor-bearing rats in this system, and 
to study the effects of adriamycin on tumor-specific immune mechanisms. 
While adriamycin is a relatively new chemotherapeutic agent, its tumor- 
icidal efficacy has been well documented in a wide variety of human 
4 
and experimental tumors. Its effectiveness in treating human osteo- 
. . i , • i • 60,61 
sarcoma is particularly striking. 
The effects of adriamycin on immune functions are more poorly 
understood, although several studies indicate that it may depress 
cellular and/or humoral responses in experimental situations. One in 
vivo investigation in an MSV-induced mouse tumor system has evaluated 
45 
the drug's action on tumor-specific immune mechanisms. As reviewed 
earlier, this report suggested that adriamycin may be somewhat immuno¬ 
suppressive, in that normally completely regressing tumors showed a 
fairly high incidence of recurrence. No in vitro data tested the 
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assumption that recurrence was related to adriamycin's immunosuppres¬ 
sive activity. 
The following sections will discuss the results of segments of 
this investigation designed to evaluate the dual effects of adriamycin 
in a rat model of osteosarcoma. 
Tumoricidal Effects of Adriamycin: 
The tumoricidal effects of adriamycin were clearly apparent in 
animals treated with adriamycin at either 1 mg/kg/day or 2 mg/kg/day 
for three consecutive days begun after tumors were already palpable. 
Tumors grew far less rapidly in the treated animals, and average tumor 
diameters were much smaller in these groups than in the untreated 
group. After 25 days of age, this difference in tumor diameters was 
highly significant (p < .001). 
Whereas untreated tumor-bearing rats were usually dead by three 
weeks of age, treated animals survived significantly longer (median 
survival in combined treatment group = 77.5 days). The lower dose of 
adriamycin seemed more effective in prolonging survival (MST =91 + 
days) than the higher dose (MST = 63.5 days). 
Finally, tumor regression was seen far more commonly in treated 
animals (12/39) than in untreated ones (0/22). This difference was 
also highly significant (p < .001). Comparable to survival data, the 
lower dose of adriamycin caused more tumor regressions (7/17, or 41%) 
than did the higher dose (5/22, or 18%). The difference in the pro¬ 
portion of regressors between treatment groups was suggestive, but not 
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si gni fi cant (p > .05). 
The tumoricidal efficacy of adriamycin has therefore been conclu¬ 
sively demonstrated by diminished tumor growth, increased survival, 
and increased proportions of regressor animals in the treatment groups. 
Adriamycin treatment at the lower dose was apparently more active than 
the higher dose in increasing the latter two indices of efficacy. 
Effects of Adriamycin on Tumor Immunity: 
The present section will discuss the following two probable effects 
of adriamycin on tumor-specific immune mechanisms as evidenced in the 
present investigation: (1) that adriamycin, at the doses and schedule 
used, and as tested by a particular in vitro method, is minimally sup¬ 
pressive to cellular tumor-specific immune mechanisms; and (2) that 
through a complex interrelation between drug, tumor, and humoral im¬ 
munity, adriamycin has elicited in vivo and in vitro enhancement. 
There are no published reports to date on the effects of adria¬ 
mycin on in vitro syngeneic tumor-specific cellular immune mechanisms. 
241 An in vitro investigation by Orsini and Mihich , however, studied 
the effects of adriamycin, administered within 2 days before or after 
antigen priming, on cellular and humoral responses to sheep red blood 
cells and allogeneic tumor cells. While both responses were somewhat 
inhibited, under certain conditions adriamycin had selective effects 
on cellular immunity. In these respects, adriamycin was equivalent 
in its irrmunosuppressive activity to daunomycin, while being less 
suppressive than Ara C or methotrexate. 
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In contrast, the results of the present investigation show no 
significant cellular suppression by adriamycin administered for three 
days beginning on day 10 after virus inoculation. Maximum cellular 
cytotoxic levels in the two treated groups (61% and 50% in the lower 
and higher dose groups, respectively) were comparable to maximum levels 
observed in the untreated group (56%). In addition, the kinetics of 
the cellular responses were similar in the three experimental groups, 
revealing early peaks of activity followed by rapid decreases to low 
levels. 
Second peaks of CMI(L) were observed in two of the three groups, 
while cellular responses in the group treated with the lower doses of 
adriamycin continued to decline. Differences in the assay of this 
group's cellular response (see Results section) may explain this ap¬ 
parent discrepancy. However, that this continued decline may have been 
due to delayed adriamycin related immunosuppression cannot be excluded. 
Both long term4 and cumulative79 toxicity by adriamycin is known to 
occur; for example, in people administered a single dose of the drug, 
leukopenia may not reach a nadir until 14 days later. In rodents 
especially, high drug levels are maintained for long periods of time 
~J ~i o ^ ^ 
in many tissues and organs, including lymphoid centers. ’ Never¬ 
theless, studies in other experimental systems^ suggest that adria- 
mycin's immunodepressive activities are dose-related. As this seems 
likely, an even greater suppression of cellular activity would be 
expected in the group treated with the higher dose of adriamycin. 
This was not observed. 
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Why, then, the disparity between these results and those of Orsini 
and Mi hich? First, the timing of drug administration may have been 
important. In the earlier study, adriamycin was administered either 
on the day of antigen inoculation or within two days before or after -- 
just at the time of lymphocyte recognition and proliferation, and an 
especially vulnerable period for inmunosuppression. Other studies 
have likewise shown a predilection for immunosuppression by adriamycin 
which was highest soon after antigen administration. Conversely, 
adriamycin in the present investigation was administered 10 days after 
virus administration, at a time when immune responses are less vulner- 
209 
able to attack. Second, the doses used in the present study, while 
therapeutically effective, may have been sufficiently low to avoid 
immunosuppression. Notable in this regard is the fact that slightly 
higher doses (3 mg/kg/day), given on the same schedule, rapidly killed 
the animals by two weeks of age. Finally, species and tumor differ¬ 
ences may have been significant in the lack of cellular suppression 
noted with adriamycin in this sytem. 
In contrast, three results of the present investigation suggest 
that there was a (possibly dose-related) tumor enhancement phenomenon 
associated with adriamycin treatment: (1) Whereas only helper acti¬ 
vity was demonstrated in the serum of untreated tumor-bearing animals, 
early helper activity in the sera of both treatment groups consistently 
and significantly converted to blocking activity by day 22; (2) Treated 
animals had significantly more long bone metastases than untreated 
animals, and the onset of these metastases corresponded precisely in 
time with maximum in vitro blocking activity. Higher dose adriamycin- 
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treated animals had more long bone metastases than lower dose-treated 
animals; and (3) There was a (nonsignificant) longer survival and higher 
incidence of regressor animals in the group treated with the lower, 
rather than higher, doses of adriamycin. It is here postulated that 
these results may bear a common pathogenesis, and that this pathogene¬ 
sis is a result of a complex relationship between drug, tumor, and 
humoral immune factors. More specifically, it is proposed that the 
tumoricidal effects of adriamycin may have caused, via cell lysis, the 
shedding of tumor antigens which, in turn, have increased the blocking 
activity in serum of treated animals. Concomitant direct effects on 
antibody populations by adriamycin may have increased the tumor en¬ 
hancing properties of these sera. Direct effects include the reason¬ 
able possibility that adriamycin has depressed helper antibodies, or 
conversely, and unlikely, the possibility that adriamycin (comparable 
to 6-mercaptopurine, cited earlier ’ ) has selectively increased 
blocking antibody populations. 
The striking finding from in vitro assays in this investigation 
was that, from day 22 onward, serum factors from treated animals de¬ 
creased tumor-specific cellular immunity. This blocking activity was 
a conversion from helper activity on day 15 in both groups, three days 
following treatment with adriamycin. After day 22, blocking activity 
persisted throughout the course in the serum of animals treated with 
adriamycin at 2 mg/kg/day, and reverted to (nonsignificant) helper 
activity on days 42 and 48 in the group treated with lower doses of 
adri amyci n. 
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It is pertinent to return to a discussion of the nature of factors 
measured by CMI(S). CMI(S) was described earlier as the net result 
of factors in serum potentially beneficial and/or deleterious to 
in vitro tumor cell proliferation. Factors deleterious to tumor cell 
proliferation include the various cytostatic and arming antibody popu¬ 
lations. Whenever CMI(S) is greater than CMI(L), these factors quan¬ 
titatively predominate in the serum tested. If these factors alone are 
present in a given serum, their eradication will never cause CMI(S) to 
be less than CMI(L); i.e., the absence of a helper effect will not 
cause blocking. 
Thus, it is obvious that serum which causes CMI(S) to be less 
than CMI(L) has a predominance of "blocking factors" in it at the 
concentrations used in the assay. It may additionally have a shortage 
of "helping factors" (arming antibodies, etc.) but it must have factors 
which block CMI(L). Blocking in vitro is usually associated with in 
vivo enhancement and widespread disease. 
Simple as this may seem, a voluminous literature has arisen at¬ 
tempting to define the nature of blocking factors, the conditions which 
cause their appearance, and their relation to enhancement of tumor 
growth in vivo. The phenomenon of enhancement was first noted in 1907 
by Flexnor and Jobling, who proposed the presence of a "tumor-promoting 
factor" to explain the unanticipated growth of transplanted tumors in 
1 OS 
rodents. Originally considered merely a laboratory curiosity, this 
"factor" has more recently become recognized as a significant in vitro 
and in vivo phenomenon accompanying rapid tumor growth in both experi¬ 
mental tumors and man. Several excellent recent articles have exhaustively 
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105 142 147 158 
reviewed the literature on blocking factors and enhancement; 5 * ’ 
however, only a brief overview is pertinent to this discussion. 
As described earlier, blocking factors may be antibody, antigen, 
or complexes of the two. Blocking antibodies appear to be related to 
the specific yG2 subclass of immunoglobulins. Antigens involved in 
enhancement include the H antigens, particularly those of the H-2 locus, 
in mice; organ-specific antigens; and most significantly, tumor-specific 
antigens. Of the last group, tumor antigens causing enhancement may 
be autochthonous, or induced by either viral infection or chemical 
carci nogens. 
Blocking factors may affect afferent, efferent or central processes. 
That is, blocking may occur at the target cell, effector cell, or 
central lymphoid centers. 
Early studies by the Hellstroms emphasized the role of antibody 
which covered target tumor cells and shielded them from attack by cyto- 
141 143 toxic cells. ’ To accomodate other data, "unblocking" antibody, 
144 
which reversed the "blocking" antibody activity had to be evoked. 
Later, evidence was presented that the blocking factors mediating 
292 
enhancement may more frequently be antigen-antibody complexes 
shielding either the target, or more likely, the effector cell. 
Some would suggest that the concept that antibody in either manner 
5 
facilitates tumor escape in vivo should now be abandoned. Support 
for their position includes reports that bursectomy and the consequent 
impairment of antibody production did not affect tumor progression in 
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chickens .64,67,191 ,266,317 Nevertheless, it is the prevailing opinion 
(shared by this investigator) that: (1) antibody mediated blocking 
does occur, but that it acts on effector, and not on target 
cells;and (2) antigen-antibody complex mediated blocking 
147 is a more common phenomenon than antibody blocking alone. In view 
of recent data^’64»67,191 ,266,317, however, it is felt by this inves¬ 
tigator that the role of antibody in causing enhancement should be de- 
emphasized. 
In contrast, evidence is mounting that antigen-associated blocking 
. ... . . , 5,7,17,64,65,67,191 ,266 ,317 is a more significant, and more conmon, event. 
5 
Indeed, Alexander has proposed that antigenic shedding by malignant 
cells, as well as by embryonic tissues, may be a fundamental mechanism 
of their escape from imnune destruction. He cites as evidence the 
fact that rat sarcoma cells that shed antigen rapidly metastasize much 
more readily than other sarcoma cells (of equivalent immunogenicity, 
and in the same animal strain) with a slow spontaneous release of anti¬ 
gen. Soluble antigens, in addition, may be poor immunogens, but may 
5 
effectively inhibit both antibody and cytotoxic cells. 
5 
Alexander has reviewed the evidence that there are three distinct 
mechanisms by which antigen gains access to the circulation in a solu¬ 
ble form: (1) By autolysis of tumor cells; e,g., as a result of a 
subcutaneous inoculum of the cells. (2) As a consequence of immune 
attack; i.e., via lysis of tumor cells consequent to host immune reac¬ 
tions. (3) By spontaneous release. Some of the evidence for spontaneous 
shedding of tumor-associated antigens has been previously described in 
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this Discussion. 
This investigator would suggest a fourth potentially significant 
mechanism of antigen release -- that caused by the tumoricidal action 
of a cytotoxic drug. Heretofore, cytotoxic drugs have been considered 
212 
only beneficial in this regard. That is, by decreasing tumor size, 
tumoricidal agents ultimately diminish antigen load, and, to the extent 
that antigen participates in blocking activity, tumoricidal agents will 
eventually decrease enhancement. This is logical, and in most cases 
212 is undoubtedly true. However, in the process of cell lysis by the 
drug, consistent with the other mechanisms of soluble antigen release, 
an overwhelming burden of soluble antigen must surely be swept into 
the circulation. It is therefore postulated that tumoricidal agents 
may paradoxically cause two antagonistic enhancement-related effects: 
an increase in blocking activity when tumor growth is rapid and drug 
cytotoxicity is quantitatively of greatest magnitude, and a later 
decrease in blocking activity when tumor burden is small and/or cells 
have become resistant to the drug's tumoricidal effects. 
Returning, at long last, to the rat model of osteosarcoma, it is 
proposed that the blocking activity seen in the sera of rats treated 
with adriamycin was secondary to antigenic shedding caused by the 
tumoricidal actions of adriamycin. Early in the disease course when 
tumor burden was small, these antigenic shedding effects of adriamycin 
were apparently quantitatively less than the tumoricidal effects of 
serum seen in both treated and untreated animals at about two weeks of 
age, when CMI(S) was consistently greater than CMI(L). While untreated 
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animal tumors grew rapidly, however, at about three weeks of age a 
plateau occurred in the graph of treated animal tumor diameters (Figure 
5). This corresponds precisely in time not only with blocking activity 
in vitro, but with the onset of long bone metastases in tumor-bearing 
treated rats as well. In addition, blocking activity persisted in 
animals treated with the higher doses of adriamycin (with presumably 
greater and more persistent tumoricidal activity), while it reverted 
to helper activity in the group treated with the lower doses (consis¬ 
tent with persistent later helper activity in untreated animals). 
The seemingly greater survival time and higher incidence of regressor 
animals in the group treated with the lower dose (vs. higher dose) of 
adriamycin is also consistent with the antigen shedding hypothesis. 
The significantly higher frequency of long bone metastases in 
treated animals is particularly fascinating. Again, it was seen that 
animals treated with the higher dose (vs_. lower dose) of adriamycin 
developed a greater number of long bone metastases. Interestingly, 
the finding of increased metastatic disease associated with cytotoxic 
drug treatment has been reported on several occasions in both experi- 
38 7? 73 1? 73 
mental tumors and man. ’ ’ Deodhar ’ noted a significant 
enhancement of metastases in a mouse sarcoma tumor model in animals 
treated with prednisone, cyclophosphamide, Ara C, or asparaginase. 
With asparaginase, metastatic enhancement was noted with doses that 
were considerably smaller than those required to produce immunosup- 
73 pression. Even more important are the results of consecutive day 
adriamycin treatment on tumor growth and metastases in the spontaneous 
79 82 
mammary carcinoma model in C3H mice noted in the Introduction. ’ 
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Whereas alternate day treatment strongly inhibited tumor growth, con¬ 
secutive day treatment increased the incidence of metastatic disease 
over untreated controls, and did not prolong survival. 
Antigenic shedding caused by drug treatment may also be clinically 
significant in man. Pertinent in this regard is the report (cited 
earlier) demonstrating earlier and more recurrences, as well as de¬ 
creased survival, in patients with resected bronchogenic carcinoma 
treated with cyclophosphamide chemotherapy, over patients left untreated. 
Other mechanisms are possible to explain the results of the present 
investigation: (1) Adriamycin may have suppressed humoral immunity 
in addition to causing antigenic shedding. The ability of adriamycin 
to depress antibody production has already been cited. That humoral 
immunity may be significant in preventing the dissemination of disease 
has been demonstrated by Alexander.6 After cannulating the thoracic 
duct and draining lymph from sarcoma-bearing rats, he returned only 
lymphoid cells to the animals (retaining the removed immunoglobulins) 
and found a significantly increased incidence of metastases over control 
animals. While antibody suppression may have played a role in meta¬ 
static enhancement in the present model, diminution of CMI(S) to block¬ 
ing levels can only be explained by the presence of additional blocking 
factors — possibly released tumor antigens. (2) Adriamycin treatment 
may have caused a selective increase in blocking antibodies. This 
explanation seems unlikely. The fact that adriamycin suppresses humoral 
immunity, and the decreasing likelihood that antibody-mediated blocking 
is a very significant event, both force one to reject this possibility. 
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(3) Adriamycin may have caused cellular immunosuppression which was 
undetectable in the in vitro assay used in the present investigation. 
This explanation seems reasonable, and is consistent with other studies 
demonstrating that minimal immunosuppression by mechanisms other than 
cytotoxic drugs (ALS treatment, sub-lethal irradiation) may enhance 
metastasis formation.^2,74,306 ^gain, additional mechanisms are needed 
to explain the blocking activity seen in the sera of treated animals. 
(4) Finally, and similar to the above explanation, minimal immunosup¬ 
pression by adriamycin per se may have enhanced tumor formation. This 
259 260 
refers to the "immunostimulation" theory of Prehn * , which suggests 
that "a little immunity may be good for a tumor (but that a lot is 
bad)". This hypothesis, as previously noted, has gained little 
support, and therefore is considered an unlikely mechanism to explain 
the results of the present investigation. 
In summary, a study of the effects of adriamycin on tumor-specific 
immune mechanisms has resulted in two significant conclusions: (1) 
Adriamycin was minimally suppressive to cellular responses at doses 
and a schedule which retarded tumor growth and prolonged survival 
times; and (2) adriamycin use was associated with in vivo and in vitro 
enhancerrent. It has been proposed that cytotoxic drugs may have a 
dual effect on the phenomenon of enhancement relative to their actions 
against tumor cells and consequent antigen load. It has been postu¬ 
lated that adriamycin treatment in the present study has caused, via 
its tumoricidal effects and antigenic shedding, an increase in serum 
blocking activity and a higher incidence of long bone metastatic di¬ 
sease. These enhancement phenomena were possibly dose-related. That 
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the net effect of adriamycin treatment was beneficial, however, is 
obvious, as tumors in treated animals progressed more slowly and re¬ 
gressed more frequently than those in untreated animals. Treated ani¬ 
mals survived significantly longer. 
It is clear that our understanding of the complicated interrela¬ 
tionships between cytotoxic drugs, tumor-immune mechanisms, and neo¬ 
plastic cells is far from complete. Critical evaluation of appropriate 
experimental tumor systems may aid in the understanding of these rela¬ 
tionships, so that host defenses against malignancy can be exploited 
to the fullest degree possible, and so that chemotherapeutic drugs may 
be used in the most rational manner. 
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V. Conclusion 
The present investigation was designed to achieve three general 
goals: (1) To document the extent of similarity of the MSV-induced 
rat osteosarcoma model to osteosarcoma in man; (2) to evaluate the 
immunobiology of this tumor-host system, with an emphasis on the kine¬ 
tics of tumor-specific immune responses;and (3) to evaluate the effects 
of adriamycin chemotherapy on the course and immune reactivity of tumor¬ 
bearing animals. 
This study substantiated the initial report of Fried!aender and 
Mitchell suggesting the excellence of the rat osteosarcoma system as 
a model of the human disease. The tumor was osteoid-producing, ini¬ 
tially localized to a long bone of an extremity, and rapidly fatal. 
The present investigation extended the study of the nature, incidence 
and distribution of metastatic dissemination. Pulmonary metastases, 
which are an integral aspect of the human disease, were documented in 
89% of necropsied animals of all ages. The tumor metastasized to a 
lesser degree to the liver, lymph nodes, and other long bones. 
Tumor-specific cellular and humoral responses were present in all 
animal groups tested from 14 to 48 days of age. Both CMI(L) and CMI(S) 
exhibited a biphasic course, with an early peak of cytotoxicity around 
days 21-26, followed by a rapid decline by days 31-33. This nadir 
was, in turn followed by a second peak of immune reactivity around 
days 39-40. Serum factors in untreated animals were consistently 
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"helper" in cytotoxic function. 
Adriamycin treatment at two doses was effective in retarding tumor 
growth and prolonging median survival times. Significantly, its use 
was not associated with suppression of tumor-specific cel 1 -mediated 
immunity. In addition, however, its use was associated with a possibly 
dose-related in vivo and in vitro enhancement phenomenon, as treated 
animals developed significantly more long bone metastases than controls 
and exhibited blocking activity in their sera. It is postulated that 
this enhancement was caused by adriamycin-induced antigenic shedding 
by the tumor, with the consequent formation of serum blocking factors. 
The rat osteosarcoma system warrants further critical evaluation 
as an excellent model of a human malignancy. The present investigation 
has posed several new questions. It is important to know the nature 
of the effector cells involved in CMI(L), the antibody populations 
responsible for the paradoxical helper activity observed in the sera 
of progressor animals, and the cause for the biphasic immune kinetics. 
More precise definition of these questions and others will undoubtedly 
increase the utility of this system, which has already enhanced our 
understanding of the intricate relationships between drug, tumor, 
and host immunity. 
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